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Summary
Background Understanding the patterns of HIV/AIDS epidemics is crucial to tracking and monitoring the progress 
of prevention and control efforts in countries. We provide a comprehensive assessment of the levels and trends of 
HIV/AIDS incidence, prevalence, mortality, and coverage of antiretroviral therapy (ART) for 1980–2017 and forecast 
these estimates to 2030 for 195 countries and territories.
Methods We determined a modelling strategy for each country on the basis of the availability and quality of data. For 
countries and territories with data from population-based seroprevalence surveys or antenatal care clinics, we 
estimated prevalence and incidence using an open-source version of the Estimation and Projection Package—a natural 
history model originally developed by the UNAIDS Reference Group on Estimates, Modelling, and Projections. For 
countries with cause-specific vital registration data, we corrected data for garbage coding (ie, deaths coded to an 
intermediate, immediate, or poorly defined cause) and HIV misclassification. We developed a process of cohort 
incidence bias adjustment to use information on survival and deaths recorded in vital registration to back-calculate 
HIV incidence. For countries without any representative data on HIV, we produced incidence estimates by pulling 
information from observed bias in the geographical region. We used a re-coded version of the Spectrum model (a 
cohort component model that uses rates of disease progression and HIV mortality on and off ART) to produce age-
sex-specific incidence, prevalence, and mortality, and treatment coverage results for all countries, and forecast these 
measures to 2030 using Spectrum with inputs that were extended on the basis of past trends in treatment scale-up 
and new infections.
Findings Global HIV mortality peaked in 2006 with 1·95 million deaths (95% uncertainty interval 1·87–2·04) and has 
since decreased to 0·95 million deaths (0·91–1·01) in 2017. New cases of HIV globally peaked in 1999 (3·16 million, 
2·79–3·67) and since then have gradually decreased to 1·94 million (1·63–2·29) in 2017. These trends, along with 
ART scale-up, have globally resulted in increased prevalence, with 36·8 million (34·8–39·2) people living with HIV 
in 2017. Prevalence of HIV was highest in southern sub-Saharan Africa in 2017, and countries in the region had ART 
coverage ranging from 65·7% in Lesotho to 85·7% in eSwatini. Our forecasts showed that 54 countries will meet the 
UNAIDS target of 81% ART coverage by 2020 and 12 countries are on track to meet 90% ART coverage by 2030. 
Forecasted results estimate that few countries will meet the UNAIDS 2020 and 2030 mortality and incidence targets.
Interpretation Despite progress in reducing HIV-related mortality over the past decade, slow decreases in incidence, 
combined with the current context of stagnated funding for related interventions, mean that many countries are not 
on track to reach the 2020 and 2030 global targets for reduction in incidence and mortality. With a growing population 
of people living with HIV, it will continue to be a major threat to public health for years to come. The pace of progress 
needs to be hastened by continuing to expand access to ART and increasing investments in proven HIV prevention 
initiatives that can be scaled up to have population-level impact.
Funding Bill & Melinda Gates Foundation, National Institute of Mental Health of the US National Institutes of Health 
(NIH), and the National Institute on Aging of the NIH.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Between 2000 and 2015, excitement around the 
Millennium Development Goals (MDGs) galvanised 
more than US$500 billion in spending on prevention, 
care, and treatment for HIV/AIDS globally.1 Despite the 
subsequent decrease in overall HIV-related mortality, 
more than 36 million people still live with HIV/AIDS, 
which continues to be the underlying cause of death for 
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almost 1 million people every year, concentrated in 
sub-Saharan Africa.2,3 Recognising the sustained threat, 
UNAIDS set targets for the years 2020 and 2030 with the 
aim of ending the epidemic by 2030.4,5 In this study, we 
estimate the current and future burden of HIV/AIDS and 
track progress towards meeting these targets.
Complementing the ambitious Sustainable Develop-
ment Goal (SDG) to end the HIV/AIDS epidemic by 
2030, UNAIDS’ 90-90-90 targets (90% of people living 
with HIV diagnosed, of whom 90% are on treatment, of 
whom 90% are virally suppressed) have been set for 
2020, and 95-95-95 targets (95% of people living with 
HIV diagnosed, of whom 95% are on treatment, of 
whom 95% are virally suppressed) for 2030.5 In 
accordance with this fast-track initiative to achieve the 
SDG goal, UNAIDS has since set targets for reducing the 
number of HIV incident cases and deaths between 2010 
and 2020 by 75% and between 2010 and 2030 by 90% for 
each country.4 Although these latest targets have helped 
to renew focus on the epidemic, measuring patterns in 
HIV/AIDS incidence, prevalence, and mortality is 
challenging, in part because of poor vital registration 
data and incomplete disease notification systems in high-
burden areas, and complex disease modelling strategies 
and methodological limitations.6 Still, compre hensive 
global estimates are needed to track progress and 
understand future burden.
In this Article, we present results from the Global 
Burden of Diseases, Injuries, and Risk Factors Study 
(GBD) 2017. We address several methodological and data-
related challenges associated with estimating HIV 
burden to provide a comprehensive and robust 
assessment of trends in HIV incidence, prevalence, and 
mortality across 195 countries and territories from 
1980 to 2017. Building on previous iterations, we 
extensively updated population estimates and incor-
porated new prevalence data from national surveys and 
antenatal care clinics. Additionally, we generated country-
level forecasts towards achieving targets associated with 
antiretroviral therapy (ART) coverage, HIV incidence, 
and HIV-related mor tality. These forecasts enable us to 
report country-specific progress towards achieving the 
following targets: a reduction in the number of HIV 
incident cases of 75% between 2010 and 2020 and 90% 
between 2010 and 2030; a reduction in the number of 
HIV deaths of 75% between 2010 and 2020 and 90% 
between 2010 and 2030; 81% (90% started, 90% retained) 
ART coverage by 2020 and 90% (95% started, 
95% retained) coverage by 2030.4,5
Methods
Study design and modelling strategy
GBD is a systematic, scientific effort to quantify the 
comparative magnitude of health loss due to diseases and 
injuries by age, sex, and geography over time. GBD 2017 
includes 195 countries and territories, 16 of which (Brazil, 
China, Ethiopia, India, Indonesia, Iran, Japan, Kenya, 
Mexico, New Zealand, Norway, Russia, South Africa, 
Research in context
Evidence before this study
The levels and trends of the global HIV/AIDS epidemic have 
been estimated by two groups: the Global Burden of Diseases, 
Injuries, and Risk Factors Study (GBD) and UNAIDS. 
We searched PubMed with the search terms hiv[MeSH] AND 
(“mortality” OR “incidence” OR “prevalence”) AND “global” 
AND (trend*), with no language restrictions, for articles 
published since database inception until Nov 7, 2018. We did 
not identify any additional studies that provided comparable 
evaluations of the global trends in the HIV/AIDS epidemic 
across countries. The last GBD on HIV was in 2015; however, it 
did not include assessment of achieving UNAIDS targets using 
forecasts of past trends and associations in the data.
Added value of this study
For GBD 2017, the main inputs for our estimation of global HIV 
trends were systematically updated. These updates include a 
comprehensive update of population estimates that are 
internally consistent with fertility and mortality estimates for 
GBD 2017, and incorporate new prevalence data from national 
surveys and antenatal care clinics. Additionally, we made 
improvements in our estimation of paediatric HIV via 
modelling of natural disease progression and incorporating 
cohort data on child antiretroviral therapy (ART) initiation and 
mortality. We also better reflected geographical differences in 
the sex-specific distribution of HIV burden on the basis of a 
model fit to the sex ratio of prevalence observed in countries 
with representative surveys. Finally, we used forecasting 
methods to generate country-level estimates towards 
achieving global targets related to ART coverage, HIV incidence, 
and HIV-related mortality by 2020 and 2030.
Implications of all the available evidence
By improving and extending existing HIV/AIDS burden 
estimates, this study provides valuable insight into progress 
towards Sustainable Development Goal 3’s target to end the 
AIDS epidemic by 2030 and the fast-track strategy to do so. 
Relative to incidence and mortality, more countries are on track 
to meet ART coverage targets of 81% (90% started, 
90% retained) by 2020 and 90% (95% started, 95% retained) by 
2030. The relative progress necessary to achieve the 2020 and 
2030 targets for reduction in incidence and mortality is not on 
pace in most countries. Renewed attention and investment in 
HIV prevention initiatives could help to restore global propensity 
to meet these targets. This study’s assessment of current trends 
and progress towards ambitious global targets provides evidence 
for decision makers to respond to current needs and plan for a 
future free of HIV/AIDS.
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Sweden, the UK, and the USA) were analysed at the 
subnational level. The conceptual and analytical framework 
for GBD, hierarchy of causes, and detailed methods have 
been published elsewhere.2,3,7 The GBD protocol is also 
available online. Herein we describe the specific methods 
used for analysing the burden of HIV for GBD 2017.
Input data for modelling HIV morbidity and mortality 
include vital registration data, household seroprevalence 
surveys, data from antenatal care clinics, demographic 
estimates (population, fertility, migration, and HIV-free 
survival rates from GBD 2017), intervention coverage 
data reported to UNAIDS including ART, prevention of 
mother-to-child transmission, HIV mortality on and off 
ART, and rates of disease progression from a systematic 
review (appendix 1 pp 2–4).
The GBD framework for HIV/AIDS aims to produce 
internally consistent estimates for HIV incidence, 
prevalence, and mortality and relies on two established 
estimation models. We used the Estimation and 
Projection Package (EPP), an HIV epidemic model 
originally developed by the UNAIDS Reference Group 
on Estimates, Modelling, and Projections.8 EPP uses 
Bayesian methods to infer force of infection from trends 
in HIV prevalence data. EPP generates incidence and 
prevalence estimates for individuals aged 15–49 years for 
both sexes combined. We also used a modified version of 
Spectrum, a compartmental model used by UNAIDS 
that ages a population over time while applying HIV 
incidence, progression, and mortality to produce age-sex-
specific HIV incidence, prevalence, and mortality.8
Multiple methodological improvements to both EPP 
and Spectrum were made for GBD estimation, including 
developing a model of ART coverage distribution as a 
function of income, age, sex, and disease progression 
that we used in Spectrum. Full details of modifications to 
EPP and Spectrum are in appendix 1 (pp 7–13).
To ensure appropriate modelling techniques, we 
grouped countries on the basis of availability and quality 
of data. Group 1 includes countries with HIV prevalence 
data from antenatal care clinics or representative 
population-based seroprevalence surveys. Group 1A 
includes countries with a peak of at least 0·5% prevalence, 
and group 1B includes countries with a peak prevalence 
of at least 0·25% plus vital registration completeness less 
than 65%. Group 2 includes all other countries, which are 
further classified as groups 2A, 2B, and 2C on the basis of 
availability of vital registration data. Group 2A locations 
have high-quality data, group 2B locations have at least 
some data, and group 2C locations have no data on HIV-
specific mortality.2 The modelling framework by country 
grouping is shown in appendix 1 (pp 5, 6).
This study was approved by the University of Washington 
Institutional Review Board (application 46665).
Incidence and prevalence estimation
For group 1 countries, we used EPP to estimate incidence 
and prevalence for individuals aged 15–49 years, for both 
sexes combined, using population-based surveys and 
antenatal care clinic data. To account for bias created by 
the differences in HIV prevalence between pregnant 
women who attended an antenatal care clinic and the 
general population, we extracted data from available 
Demographic and Health Surveys on HIV prevalence 
among pregnant women who gave birth in the past year 
and who attended an antenatal care clinic. For antenatal 
care bias adjustment, we input this data into a regression 
model with regional random effects to generate country-
specific prior distributions where surveys were available 
and regional prior distributions for locations without a 
survey. We then used the incidence and prevalence 
results from EPP as inputs in Spectrum to further 
disaggregate to age-sex-specific HIV incidence and 
prevalence. We used the sex ratio of prevalence from 
population-based surveys to inform the sex-splitting 
assumptions for adults in Spectrum, and applied default 
age-splitting assumptions from Spectrum.8 We calculated 
vertical transmission as a function of prevention of 
mother-to-child transmission inputs and age-specific 
fertility rates adjusted to account for differential fertility 
among women who were HIV positive.
For group 2 countries, we developed a process called 
cohort incidence bias adjustment to estimate incidence 
and prevalence using mortality data. We ran a first stage 
of Spectrum to generate initial incidence, prevalence, 
and mortality curves, along with incidence cohort 
survival. We then calculated the bias between Spectrum 
mortality estimates and smoothed vital registration data 
for each year, which we used along with Spectrum cohort 
survival estimates to adjust incidence (appendix 1 
pp 11–13). To account for sensitivity in our estimates to 
input incidence, we ran the first stage of Spectrum using 
various input incidence curves and selected the option 
with the smallest resulting bias in mortality estimates. 
We ran a second stage of Spectrum using adjusted 
incidence to produce age-sex-specific incidence and 
prevalence estimates. In countries with high-quality case 
notifi cation data, we scaled incidence results to align 
with case reports after accounting for an assumed 
average of 5 years’ lag between infection and diagnosis.9
Mortality estimation
We undertook a meta-analysis of cohort studies to derive 
on-ART and off-ART mortality as inputs into Spectrum 
and EPP. We estimated age-sex-specific, CD4-specific, 
region-specific, and duration-specific on-ART mortality 
using cohort data after correcting for loss to follow-up 
(appendix 1 pp 4–7). We jointly estimated off-ART 
mortality and CD4 progression via an optimisation 
process that found a best fit to survival curves from 
cohort studies.
For group 1 countries, we generated age-sex-specific 
HIV mortality estimates in Spectrum using the incidence 
and prevalence estimated in EPP. For group 2 countries, 
we adjusted vital registration data for incompleteness 
See Online for appendix 1
For the Global Burden of 
Diseases, Injuries, and Risk 
Factors Study protocol see 
http://www.healthdata.org/gbd/
about/protocol
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and garbage coding (ie, deaths coded to an intermediate, 
immediate, or poorly defined cause).2 We further 
corrected the data for HIV misclassification by identifying 
causes of death that deviated from expected age patterns 
of mortality in years with known HIV epidemics, and 
excess deaths were attributed to HIV. We used 
spatiotemporal Gaussian process regression to smooth 
and complete the time series of adjusted vital registration 
data (appendix 1 p 11). For groups 2A and 2B, we used the 
smoothed vital registration data to inform Spectrum-
estimated mortality through the cohort incidence bias 
adjustment process. In group 2C countries, we leveraged 
spatial information by sampling cohort incidence bias 
adjustment-generated incidence-adjustment scalars in 
the region, which were then input into Spectrum to 
create mortality estimates.
The GBD framework produced three distinct sources 
of HIV mortality estimates: HIV mortality results from 
Spectrum; estimated excess HIV mortality from the all-
cause mortality process; and smoothed HIV-specific 
mortality from vital registration data. 10 For group 1 
countries, we used an ensemble approach to reconcile 
the differences between HIV mortality estimated by 
Spectrum and by the all-cause mortality process and 
generate final HIV mortality. In group 1 countries, EPP 
and Spectrum estimates were largely driven by HIV 
prevalence data and mortality estimates generated from 
cohort data, whereas the all-cause mortality process was 
primarily based on sibling survival data. For individuals 
aged 15 years and older, the ensemble model averaged 
HIV mortality estimates from the two processes with 
equal weights. For individuals younger than 15 years, we 
applied the fraction of deaths due to HIV in Spectrum to 
estimated all-cause mortality to generate HIV-specific 
mortality and mortality from all other causes (HIV-free 
mortality). In group 2A countries, we estimated mortality 
only from vital registration data, and for group 2B and 2C 
countries we only used Spectrum results.
Forecasting to 2030
We forecasted HIV incidence, prevalence, mortality, and 
treatment coverage through to 2030 in Spectrum using 
input parameters extended to 2030. We forecasted the 
adult ART coverage input on the basis of forecasted ART 
price, HIV spending on care and treatment, and lag-
distributed income (ie, gross domestic product per capita 
that has been smoothed over the preceding 10 years). We 
modelled country-year-specific annual ART price per 
patient using Gaussian process regression with data from 
the Global Price Reporting Mechanism.11 We calculated 
the annualised rate of change of per-capita expenditure 
on HIV care and treatment in each country since 2010. 
We then forecast expenditure on HIV care and treatment 
for each country using the 50th percentile annualised rate 
of change across countries.1 We calculated annual dose-
equivalents of ART by dividing spending by ART price, 
and we used logistic regression to model the association 
between annual dose-equivalents and ART coverage. We 
forecasted other treatment coverage inputs to Spectrum, 
such as child ART coverage and prevention of mother-to-
child transmission, using the same approach based on 
the 50th percentile annualised rate of change observed 
across countries. Forecasting the incidence input had two 
steps. First, we calculated counterfactual incidence 
(ie, expected incidence in the absence of ART) using an 
assumption of 70% viral suppression among those on 
treatment,12 then we forecast counterfactual incidence 
using the 50th percentile annualised rate of change 
observed across countries in the previous 5 years. Because 
the forecasted incidence was derived from the counter-
factual incidence using forecasted ART coverage, the final 
forecasted incidence changed in response to both the 
underlying secular trend and improvements in ART 
coverage. We used forecasted demographic inputs that 
were estimated for each location,13 then we ran Spectrum 
for all locations. Full details on the methods for forecasting 
are in appendix 1 (pp 17–22). We used the mean values 
(rounded to the nearest integer) of the resultant HIV 
Figure 1: Global HIV incidence, prevalence, mortality, and people on ART, by sex, for all ages, 1980–2017
Shaded areas are 95% uncertainty intervals. ART=antiretroviral therapy.
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of change in 
new infections
Annualised rate of change in 
HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–17
Global 966 000 
(786 000 to 
1 180 000)
976 000 
(835 000 to 
1 120 000)
1 940 000 
(1 630 000 to 
2 290 000)
446 000 
(417 000 to 
479 000)
508 000 
(483 000 to 
540 000)
954 000 
(907 000 to 
1 010 000)
–0·4% 
(–1·2 to 0·3)
–3·0% 
(–4·5 to –1·5)
8·5% 
(7·8 to 9·1)
–8·3% 
(–8·7 to –7·9)
Low SDI 259 000 
(176 000 to 
378 000)
177 000 
(124 000 to 
257 000)
436 000 
(303 000 to 
627 000)
132 000 
(120 000 to 
147 000)
131 000 
(121 000 to 
143 000)
262 000 
(244 000 to 
286 000)
–5·2% 
(–6·2 to –4·2)
–5·9% 
(–9·4 to –2·0)
4·6% 
(3·6 to 5·7)
–12·4% 
(–13·0 to –11·8)
Low-middle 
SDI
359 000 
(271 000 to 
459 000)
278 000 
(212 000 to 
356 000)
636 000 
(487 000 to 
808 000)
192 000 
(170 000 to 
217 000)
184 000 
(163 000 to 
207 000)
375 000 
(338 000 to 
416 000)
–1·6% 
(–2·8 to –0·5)
–4·1% 
(–6·1 to –2·0)
11·3% 
(10·0 to 12·4)
–8·5% 
(–9·1 to –7·8)
Middle SDI 240 000 
(196 000 to 
287 000)
280 000 
(245 000 to 
317 000)
521 000 
(450 000 to 
591 000)
105 000 
(94 500 to 
119 000)
153 000 
(143 000 to 
165 000)
258 000 
(241 000 to 
278 000)
6·0% 
(4·0 to 8·2)
–3·7% 
(–5·3 to –2·1)
18·6% 
(17·9 to 19·3)
–7·8% 
(–8·5 to –7·2)
High-middle 
SDI
80 800 
(69 100 to 
99 400)
167 000 
(139 000 to 
198 000)
247 000 
(210 000 to 
297 000)
14 200 
(13 700 to 
14 800)
31 500 
(30 800 to 
32 700)
45 700 
(44 600 to 
47 500)
3·7% 
(3·2 to 4·3)
7·5% 
(5·6 to 9·2)
4·6% 
(4·5 to 4·8)
0·7% 
(0·5 to 1·1)
High SDI 26 700 
(15 300 to 
39 200)
73 100 
(42 900 to 
107 000)
99 800 
(58 300 to 
146 000)
3170 
(3140 to 
3200)
8700 
(8610 to 
8800)
11 900 
(11 800 to 
12 000)
–2·5% 
(–3·9 to –1·0)
1·9% 
(–0·8 to 3·2)
–5·7% 
(–5·8 to –5·7)
–5·3% 
(–5·4 to –5·2)
Central 
Europe, 
eastern 
Europe, and 
central Asia
59 300 
(49 400 to 
74 000)
121 000 
(94 800 to 
149 000)
180 000 
(146 000 to 
222 000)
8260 
(8170 to 
8350)
18 700 
(18 400 to 
18 900)
26 900 
(26 700 to 
27 100)
8·1% 
(7·0 to 9·2)
11·7% 
(9·1 to 13·5)
7·7% 
(7·6 to 7·8)
1·8% 
(1·7 to 2·0)
Central Asia 3280 
(2200 to 4480)
4030 
(2950 to 5110)
7300 
(5200 to 9550)
398 
(377 to 419)
902 
(869 to 935)
1300 
(1260 to 1340)
4·2% 
(2·2 to 6·3)
7·2% 
(3·7 to 9·8)
6·8% 
(6·6 to 7·2)
–0·6% 
(–1·0 to –0·2)
Armenia 65·3 
(46·1 to 91·6)
99·6 
(67·6 to 154)
165 
(120 to 241)
5·7 
(5·2 to 6·2)
18·0 
(17·1 to 19·0)
23·7 
(22·7 to 24·8)
21·1% 
(11·6 to 59·7)
7·5% 
(4·1 to 12·7)
11·7% 
(11·3 to 12·0)
10·7% 
(10·0 to 11·3)
Azerbaijan 91·2 
(60·5 to 127)
260 
(157 to 416)
351 
(222 to 535)
7·8 
(5·5 to 9·8)
23·7 
(17·9 to 28·3)
31·5 
(23·8 to 37·8)
2·4% 
(–5·8 to 5·8)
9·5% 
(5·2 to 12·9)
6·4% 
(3·5 to 14·8)
–8·0% 
(–11·2 to –5·0)
Georgia 108 
(74·0 to 160)
283 
(181 to 491)
391 
(256 to 641)
8·5 
(7·9 to 9·1)
25·9 
(24·5 to 27·4)
34·4 
(32·9 to 35·9)
18·4% 
(12·8 to 25·9)
2·2% 
(–0·0 to 4·4)
8·7% 
(8·3 to 9·1)
17·6% 
(17·0 to 18·3)
Kazakhstan 988 
(640 to 1440)
1510 
(1000 to 1880)
2500 
(1670 to 3220)
72·6 
(67·2 to 78·2)
186 
(175 to 198)
258 
(246 to 271)
2·5% 
(0·9 to 4·2)
12·1% 
(8·0 to 14·2)
7·8% 
(7·5 to 8·2)
–2·1% 
(–2·7 to –1·6)
Kyrgyzstan 457 
(291 to 719)
447 
(275 to 707)
904 
(575 to 1390)
53·9 
(50·2 to 57·6)
133 
(126 to 140)
187 
(179 to 194)
8·9% 
(7·3 to 11·1)
6·2% 
(1·1 to 10·7)
9·2% 
(8·8 to 9·5)
1·6% 
(1·0 to 2·2)
Mongolia 11·5 
(2·3 to 29·5)
48·7 
(11·3 to 105)
60·2 
(14·9 to 132)
3·8 
(0·3 to 11·1)
16·1 
(1·6 to 32·9)
19·9 
(2·1 to 44·0)
25·1% 
(47·5 to 58·1)
6·7% 
(0·2 to 11·6)
35·4% 
(43·1 to 49·1)
8·2% 
(–11·0 to 13·4)
Tajikistan 419 
(184 to 633)
156 
(95·4 to 224)
575 
(280 to 819)
29·8 
(21·3 to 44·2)
14·7 
(12·2 to 18·1)
44·5 
(34·3 to 60·5)
2·4% 
(–0·6 to 4·5)
9·1% 
(2·4 to 13·3)
14·1% 
(11·0 to 18·8)
–13·5% 
(–16·5 to –9·5)
Turkmenistan 44·6 
(32·4 to 69·4)
116 
(88·5 to 169)
160 
(122 to 236)
26·4 
(24·4 to 28·8)
73·0 
(68·7 to 77·6)
99·5 
(94·6 to 105)
–6·4% 
(–10·1 to –1·7)
2·2% 
(0·3 to 4·4)
2·5% 
(2·2 to 2·9)
–2·5% 
(–3·1 to –1·8)
Uzbekistan 1090 
(330 to 1910)
1100 
(305 to 2000)
2200 
(650 to 3780)
189 
(174 to 204)
413 
(390 to 436)
601 
(575 to 628)
5·0% 
(0·8 to 11·4)
5·1% 
(–7·3 to 11·6)
5·1% 
(4·8 to 5·4)
1·0% 
(0·3 to 1·5)
Central Europe 529 
(401 to 669)
1600 
(1260 to 2120)
2130 
(1670 to 2770)
126 
(118 to 144)
395 
(356 to 462)
521 
(476 to 604)
6·3% 
(4·4 to 8·0)
–0·1% 
(–2·1 to 1·4)
–0·0% 
(–0·4 to 0·8)
–0·9% 
(–1·7 to –0·1)
Albania 0·9 
(0·7 to 1·4)
2·1 
(1·5 to 3·0)
3·0 
(2·2 to 4·3)
0·4 
(0·4 to 0·5)
0·9 
(0·8 to 1·0)
1·3 
(1·1 to 1·5)
0·4% 
(–0·4 to 1·3)
2·0% 
(0·2 to 3·7)
2·9% 
(2·0 to 4·2)
–3·6% 
(–4·8 to –2·4)
Bosnia and 
Herzegovina
1·2 
(0·8 to 1·6)
2·2 
(1·6 to 3·2)
3·4 
(2·5 to 4·4)
0·5 
(0·5 to 0·6)
1·0 
(0·9 to 1·2)
1·5 
(1·4 to 1·7)
–3·9% 
(–5·1 to –2·5)
4·5% 
(2·6 to 6·1)
–2·0% 
(–3·4 to 0·0)
–3·9% 
(–4·7 to –3·1)
Bulgaria 28·1 
(22·9 to 33·9)
100 
(66·9 to 126)
128 
(93·7 to 156)
12·5 
(11·8 to 13·3)
42·1 
(39·9 to 44·3)
54·6 
(52·3 to 57·0)
1·5% 
(–2·5 to 56·2)
3·3% 
(1·2 to 4·8)
6·7% 
(6·4 to 7·0)
–4·7% 
(–5·2 to –4·2)
Croatia 10·9 
(5·5 to 15·1)
34·1 
(17·9 to 48·0)
44·9 
(23·6 to 61·9)
2·1 
(2·0 to 2·3)
6·8 
(6·5 to 7·2)
9·0 
(8·7 to 9·3)
1·7% 
(0·0 to 3·2)
1·9% 
(–3·9 to 6·0)
–2·6% 
(–2·9 to –2·2)
6·7% 
(6·2 to 7·3)
Czech 
Republic
17·6 
(9·3 to 28·4)
87·8 
(38·0 to 148)
105 
(48·0 to 165)
7·4 
(6·9 to 7·9)
16·4 
(15·6 to 17·2)
23·7 
(22·9 to 24·6)
9·2% 
(8·0 to 10·3)
2·8% 
(–3·7 to 5·6)
3·9% 
(3·6 to 4·2)
5·4% 
(4·9 to 5·9)
Hungary 28·8 
(17·5 to 50·9)
99·4 
(63·4 to 158)
128 
(86·0 to 193)
8·1 
(7·5 to 8·7)
31·8 
(30·2 to 33·7)
39·8 
(38·1 to 41·7)
–1·5% 
(–3·0 to 0·2)
3·1% 
(1·2 to 5·6)
–4·2% 
(–4·5 to –3·8)
–7·6% 
(–8·2 to –7·0)
Macedonia 4·0 
(3·0 to 5·2)
5·4 
(4·0 to 7·4)
9·3 
(7·1 to 12·2)
0·7 
(0·5 to 0·9)
1·0 
(0·8 to 1·1)
1·7 
(1·4 to 2·0)
9·9% 
(7·6 to 11·8)
1·8% 
(–0·7 to 4·0)
8·6% 
(7·3 to 10·1)
–2·2% 
(–4·2 to –0·9)
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Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–17
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Montenegro 1·9 
(1·4 to 2·4)
4·7 
(3·6 to 6·2)
6·6 
(5·1 to 8·4)
0·6 
(0·4 to 0·9)
0·7 
(0·6 to 0·8)
1·4 
(1·1 to 1·7)
3·9% 
(1·8 to 5·7)
3·1% 
(1·0 to 4·8)
4·9% 
(3·2 to 6·3)
–2·8% 
(–6·1 to –0·0)
Poland 151 
(78·7 to 246)
532 
(239 to 981)
683 
(319 to 1220)
32·0 
(30·2 to 33·9)
112 
(106 to 118)
144 
(138 to 150)
5·2% 
(2·8 to 7·6)
0·3% 
(–5·6 to 2·7)
5·3% 
(5·0 to 5·6)
–2·2% 
(–2·7 to –1·6)
Romania 258 
(185 to 323)
591 
(417 to 778)
849 
(634 to 1050)
47·9 
(45·1 to 51·2)
118 
(112 to 123)
165 
(160 to 171)
10·0% 
(7·6 to 12·6)
–0·1% 
(–2·4 to 1·7)
–2·8% 
(–3·2 to –2·4)
2·7% 
(2·1 to 3·2)
Serbia 18·5 
(11·6 to 30·9)
112 
(73·2 to 181)
130 
(85·9 to 209)
12·3 
(6·2 to 28·9)
60·2 
(23·9 to 126)
72·5 
(30·3 to 156)
8·3% 
(4·6 to 60·9)
–4·5% 
(–7·3 to –1·6)
3·7% 
(–0·3 to 54·4)
1·9% 
(–4·5 to 6·9)
Slovakia 6·5 
(4·7 to 8·3)
16·5 
(11·2 to 25·2)
23·0 
(16·2 to 33·5)
1·2 
(0·8 to 1·7)
2·7 
(2·1 to 3·3)
3·9 
(3·0 to 4·9)
4·2% 
(–1·5 to 48·2)
2·0% 
(–0·1 to 4·3)
7·7% 
(4·1 to 38·6)
–0·1% 
(–3·7 to 2·0)
Slovenia 1·6 
(1·1 to 2·5)
9·9 
(6·7 to 15·2)
11·5 
(7·9 to 17·8)
0·4 
(0·3 to 0·4)
2·1 
(2·0 to 2·2)
2·5 
(2·4 to 2·6)
–1·2% 
(–4·7 to 48·3)
4·1% 
(2·3 to 5·8)
–1·8% 
(–2·1 to –1·4)
–4·8% 
(–5·3 to –4·2)
Eastern Europe 55 500 
(46 300 to 
68 700)
115 000 
(90 500 to 
142 000)
171 000 
(139 000 to 
209 000)
7730 
(7650 to 
7820)
17 400 
(17 100 to 
17 600)
25 100 
(24 800 to 
25 300)
8·8% 
(7·6 to 10·1)
12·4% 
(9·8 to 14·3)
8·4% 
(8·3 to 8·5)
2·1% 
(2·0 to 2·3)
Belarus 1280 
(781 to 1930)
1260 
(935 to 1680)
2540 
(1730 to 3610)
94·1 
(89·0 to 99·4)
210 
(194 to 226)
304 
(288 to 320)
7·8% 
(0·9 to 66·8)
9·8% 
(6·8 to 12·6)
10·6% 
(10·1 to 11·0)
0·3% 
(–0·4 to 1·0)
Estonia 41·6 
(30·5 to 61·3)
165 
(119 to 238)
207 
(152 to 298)
7·8 
(7·4 to 8·2)
29·4 
(27·3 to 31·7)
37·2 
(35·0 to 39·5)
27·4% 
(24·5 to 30·8)
–1·8% 
(–5·3 to 2·9)
25·5% 
(25·1 to 25·9)
0·2% 
(–0·6 to 1·1)
Latvia 203 
(134 to 238)
255 
(204 to 313)
458 
(345 to 528)
57·1 
(54·4 to 59·7)
69·4 
(64·8 to 74·0)
126 
(121 to 132)
4·0% 
(2·9 to 4·9)
7·1% 
(3·8 to 8·5)
5·5% 
(5·1 to 5·9)
5·1% 
(4·5 to 5·8)
Lithuania 41·1 
(10·0 to 61·9)
94·0 
(26·1 to 146)
135 
(36·0 to 196)
42·3 
(40·3 to 44·6)
24·7 
(23·1 to 26·4)
67·0 
(64·5 to 69·7)
6·4% 
(4·3 to 62·5)
–0·1% 
(–12·3 to 2·7)
9·2% 
(8·9 to 9·6)
0·6% 
(0·0 to 1·2)
Moldova 377 
(267 to 548)
398 
(287 to 560)
775 
(569 to 1080)
49·5 
(46·8 to 52·1)
124 
(116 to 132)
173 
(164 to 182)
8·5% 
(0·9 to 14·6)
1·8% 
(–0·5 to 3·6)
10·7% 
(10·2 to 11·1)
–3·1% 
(–3·9 to –2·4)
Russia 41 700 
(34 600 to 
51 600)
97 100 
(78 500 to 
122 000)
139 000 
(115 000 to 
171 000)
5480 
(5430 to 
5520)
13 800 
(13 700 to 
14 000)
19 300 
(19 100 to 
19 500)
10·0% 
(8·8 to 12·3)
13·2% 
(10·3 to 15·5)
7·0% 
(6·9 to 7·0)
5·9% 
(5·8 to 6·0)
Ukraine 11 800 
(7920 to 
16 500)
16 100 
(9210 to 
20 500)
27 900 
(19 000 to 
35 300)
2000 
(1930 to 
2080)
3070 
(2930 to 
3220)
5080 
(4920 to 
5240)
5·9% 
(2·8 to 8·1)
9·7% 
(6·9 to 12·6)
10·7% 
(10·5 to 11·0)
–5·9% 
(–6·3 to –5·5)
High-income 34 600 
(19 800 to 
51 000)
88 600 
(52 700 to 
130 000)
123 000 
(72 600 to 
179 000)
3750 
(3720 to 
3790)
10 200 
(10 100 to 
10 300)
13 900 
(13 800 to 
14 000)
–1·8% 
(–3·1 to –0·4)
2·0% 
(–0·2 to 3·2)
–5·0% 
(–5·1 to –5·0)
–4·9% 
(–4·9 to –4·8)
Australasia 417 
(228 to 745)
1160 
(691 to 1760)
1580 
(950 to 2270)
20·6 
(19·8 to 21·4)
65·9 
(63·8 to 68·1)
86·6 
(84·4 to 88·9)
–0·3% 
(–2·8 to 1·9)
2·5% 
(1·2 to 4·0)
–8·4% 
(–8·7 to –8·2)
–5·9% 
(–6·2 to –5·6)
Australia 378 
(202 to 698)
1020 
(591 to 1560)
1390 
(834 to 2030)
18·7 
(17·9 to 19·5)
57·9 
(55·8 to 60·0)
76·6 
(74·4 to 78·9)
–1·0% 
(–3·7 to 1·4)
2·8% 
(1·5 to 4·3)
–8·2% 
(–8·4 to –7·9)
–6·3% 
(–6·7 to –6·0)
New Zealand 38·9 
(20·7 to 59·8)
147 
(68·4 to 233)
186 
(89·6 to 293)
1·9 
(1·9 to 2·0)
8·1 
(7·8 to 8·3)
10·0 
(9·7 to 10·3)
5·7% 
(4·1 to 8·9)
0·6% 
(–4·2 to 3·7)
–10·4% 
(–10·7 to –10·2)
–2·6% 
(–3·0 to –2·2)
High-income 
Asia Pacific
669 
(396 to 955)
2310 
(1240 to 3660)
2970 
(1680 to 4530)
79·9 
(78·1 to 81·9)
312 
(302 to 322)
392 
(382 to 402)
5·0% 
(2·4 to 8·5)
0·2% 
(–4·5 to 2·7)
4·5% 
(4·3 to 4·7)
–2·2% 
(–2·5 to –1·9)
Brunei 7·9 
(4·3 to 12·8)
27·8 
(15·1 to 45·9)
35·7 
(19·8 to 57·7)
1·4 
(1·1 to 1·6)
3·3 
(2·8 to 3·9)
4·7 
(4·0 to 5·4)
5·3% 
(3·9 to 6·6)
3·7% 
(0·4 to 5·8)
6·4% 
(5·0 to 8·0)
–1·6% 
(–3·9 to 0·3)
Japan 426 
(212 to 624)
1040 
(501 to 1510)
1460 
(724 to 2130)
59·4 
(58·1 to 60·6)
147 
(144 to 151)
207 
(203 to 210)
4·4% 
(2·8 to 6·1)
1·9% 
(–2·1 to 3·5)
5·8% 
(5·8 to 6·0)
–2·9% 
(–3·0 to –2·7)
Singapore 56·0 
(22·3 to 90·6)
113 
(62·9 to 196)
169 
(90·1 to 268)
3·1 
(2·8 to 3·5)
29·6 
(27·5 to 31·7)
32·7 
(30·6 to 34·9)
–5·6% 
(–8·1 to –4·0)
–1·1% 
(–3·8 to 1·6)
7·5% 
(6·9 to 8·1)
–6·7% 
(–7·7 to –5·8)
South Korea 180 
(50·8 to 296)
1130 
(273 to 2280)
1310 
(327 to 2530)
16·1 
(14·9 to 17·4)
131 
(122 to 142)
148 
(138 to 157)
8·3% 
(1·7 to 62·6)
–2·6% 
(–13·6 to 2·2)
1·0% 
(0·5 to 1·4)
–0·7% 
(–1·5 to 0·1)
High-income 
North America
15 600 
(6270 to 
24 700)
39 200 
(16 100 to 
62 300)
54 800 
(22 600 to 
86 200)
2140 
(2110 to 
2170)
5480 
(5400 to 
5550)
7620 
(7540 to 
7690)
–2·3% 
(–3·8 to 0·9)
1·6% 
(–4·7 to 3·6)
–6·2% 
(–6·2 to –6·1)
–6·0% 
(–6·2 to –5·9)
Canada 942 
(434 to 1490)
2590 
(1050 to 4310)
3530 
(1520 to 5660)
72·2 
(68·5 to 76·3)
202 
(189 to 215)
274 
(261 to 287)
–1·8% 
(–3·5 to 1·9)
3·9% 
(–1·7 to 6·8)
–4·8% 
(–5·1 to –4·6)
–5·6% 
(–6·2 to –5·0)
Greenland 6·2 
(2·2 to 11·1)
4·7 
(2·1 to 7·7)
10·9 
(4·6 to 18·1)
0·8 
(0·6 to 1·0)
0·9 
(0·6 to 1·1)
1·6 
(1·3 to 2·0)
–0·8% 
(–2·5 to 2·2)
4·2% 
(–2·2 to 6·6)
0·1% 
(–1·3 to 1·7)
–5·0% 
(–7·6 to –3·4)
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Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–17
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USA 14 700 
(5440 to 
23 600)
36 600 
(14 300 to 
58 900)
51 300 
(19 700 to 
81 300)
2070 
(2040 to 
2100)
5270 
(5200 to 
5340)
7340 
(7260 to 
7420)
–2·3% 
(–3·9 to 1·0)
1·5% 
(–5·6 to 3·6)
–6·2% 
(–6·3 to –6·2)
–6·0% 
(–6·2 to –5·9)
Southern Latin 
America
6630 
(3020 to 
12 300)
10 500 
(5830 to 
17 100)
17 100 
(9040 to 
28 300)
673 
(657 to 690)
1730 
(1700 to 1770)
2400 
(2370 to 
2440)
1·7% 
(0·3 to 3·2)
1·8% 
(0·8 to 3·0)
5·0% 
(4·9 to 5·1)
–0·9% 
(–1·1 to –0·7)
Argentina 5750 
(2490 to 
11 300)
6430 
(3330 to 
10 900)
12 200 
(6000 to 
21 000)
548 
(533 to 565)
1170 
(1140 to 
1200)
1720 
(1680 to 
1750)
1·0% 
(–0·6 to 2·6)
1·0% 
(–0·3 to 2·7)
4·7% 
(4·6 to 4·8)
–1·4% 
(–1·7 to –1·2)
Chile 682 
(339 to 1180)
3440 
(1850 to 
5490)
4120 
(2220 to 6690)
85·3 
(82·9 to 87·7)
419 
(407 to 430)
505 
(493 to 516)
5·0% 
(3·8 to 6·2)
3·7% 
(2·8 to 4·7)
6·3% 
(6·1 to 6·5)
0·6% 
(0·3 to 0·9)
Uruguay 193 
(131 to 279)
635 
(527 to 781)
828 
(671 to 1040)
39·8 
(38·8 to 40·8)
141 
(137 to 144)
181 
(177 to 184)
0·4% 
(–6·0 to 4·8)
5·9% 
(3·5 to 8·5)
7·1% 
(7·0 to 7·3)
–0·5% 
(–0·8 to –0·2)
Western 
Europe
11 200 
(6590 to 
16 200)
35 500 
(21 200 to 
51 600)
46 700 
(27 800 to 
67 200)
836 
(818 to 856)
2610 
(2550 to 
2670)
3450 
(3390 to 
3510)
–2·7% 
(–4·8 to –1·1)
2·0% 
(0·2 to 3·4)
–4·9% 
(–5·0 to –4·8)
–5·4% 
(–5·6 to –5·2)
Andorra 0·6 
(0·0 to 2·8)
4·0 
(0·2 to 19·1)
4·6 
(0·3 to 21·4)
0·1 
(0·0 to 0·4)
0·3 
(0·0 to 1·5)
0·4 
(0·0 to 1·9)
–0·6% 
(–11·1 to 7·0)
0·4% 
(–6·3 to 7·3)
–3·6% 
(–10·2 to 1·4)
–8·5% 
(–12·8 to –3·2)
Austria 169 
(93·4 to 248)
518 
(273 to 798)
688 
(369 to 1030)
8·5 
(8·0 to 9·0)
29·5 
(27·9 to 31·2)
38·0 
(36·3 to 39·8)
–0·0% 
(–6·1 to 65·4)
0·8% 
(–2·0 to 4·5)
–2·0% 
(–2·4 to –1·6)
–4·7% 
(–5·4 to –4·1)
Belgium 350 
(153 to 541)
787 
(298 to 1310)
1140 
(444 to 1850)
20·0 
(19·0 to 21·2)
41·8 
(39·7 to 44·3)
61·9 
(59·4 to 64·7)
1·6% 
(–0·9 to 3·6)
–0·2% 
(–6·0 to 3·4)
–4·3% 
(–4·6 to –4·0)
–2·5% 
(–3·0 to –1·9)
Cyprus 15·2 
(10·4 to 21·0)
96·0 
(68·3 to 138)
111 
(79·5 to 158)
0·4 
(0·4 to 0·5)
1·4 
(1·2 to 1·7)
1·9 
(1·6 to 2·1)
6·1% 
(3·6 to 9·2)
5·0% 
(2·7 to 7·6)
4·4% 
(2·5 to 6·0)
–3·7% 
(–5·2 to –2·1)
Denmark 155 
(53·8 to 264)
253 
(125 to 457)
408 
(206 to 643)
7·7 
(7·2 to 8·2)
19·2 
(18·1 to 20·2)
26·9 
(25·8 to 28·1)
–2·3% 
(–4·0 to –0·8)
1·1% 
(–5·0 to 3·8)
–5·9% 
(–6·3 to –5·5)
–3·4% 
(–4·1 to –2·9)
Finland 34·5 
(9·7 to 59·1)
127 
(34·0 to 223)
161 
(43·7 to 280)
1·7 
(1·6 to 1·8)
4·8 
(4·5 to 5·1)
6·5 
(6·2 to 6·8)
2·6% 
(0·5 to 4·7)
–1·2% 
(–10·7 to 4·0)
–0·2% 
(–0·6 to 0·1)
–10·2% 
(–10·8 to –9·6)
France 1620 
(734 to 2880)
3570 
(1660 to 
6480)
5190 
(2670 to 8610)
134 
(126 to 142)
358 
(337 to 380)
491 
(469 to 514)
–3·1% 
(–6·1 to –1·1)
0·3% 
(–1·6 to 2·0)
–8·7% 
(–8·9 to –8·5)
–6·1% 
(–6·7 to –5·6)
Germany 1460 
(884 to 2050)
4980 
(2920 to 7180)
6430 
(3810 to 9130)
102 
(96·3 to 107)
363 
(345 to 381)
465 
(446 to 483)
1·3% 
(–0·2 to 2·2)
2·7% 
(–0·2 to 6·7)
–7·0% 
(–7·2 to –6·7)
–2·5% 
(–3·0 to –2·1)
Greece 54·8 
(35·3 to 75·5)
459 
(280 to 805)
514 
(326 to 854)
6·0 
(5·6 to 6·4)
23·6 
(22·3 to 24·8)
29·6 
(28·2 to 30·9)
1·9% 
(–0·1 to 4·0)
0·1% 
(–2·1 to 2·6)
–4·0% 
(–4·4 to –3·6)
3·3% 
(2·7 to 3·9)
Iceland 0·0 
(0·0 to 0·1)
20·1 
(8·9 to 30·3)
20·1 
(8·9 to 30·3)
0·0 
(0·0 to 0·0)
0·8 
(0·8 to 0·9)
0·9 
(0·8 to 0·9)
–0·1% 
(–2·5 to 1·9)
–1·2% 
(–8·5 to 3·0)
–4·3% 
(–4·8 to –4·0)
–4·4% 
(–5·2 to –3·7)
Ireland 148 
(56·6 to 225)
414 
(153 to 665)
562 
(206 to 884)
2·7 
(2·5 to 2·9)
7·1 
(6·7 to 7·6)
9·8 
(9·3 to 10·3)
–0·9% 
(–2·8 to 0·9)
4·1% 
(–4·3 to 6·8)
–0·5% 
(–0·9 to –0·1)
–5·4% 
(–6·0 to –4·7)
Israel 202 
(106 to 288)
485 
(253 to 695)
688 
(377 to 970)
12·8 
(12·2 to 13·5)
28·6 
(27·1 to 30·1)
41·4 
(39·8 to 43·0)
3·1% 
(0·6 to 5·8)
0·0% 
(–4·8 to 4·8)
–1·2% 
(–1·5 to –0·9)
–4·7% 
(–5·3 to –4·2)
Italy 1580 
(962 to 2300)
5560 
(3360 to 8330)
7140 
(4260 to 10 600)
156 
(146 to 166)
505 
(479 to 533)
661 
(634 to 692)
–5·5% 
(–11·6 to 2·7)
3·7% 
(0·8 to 7·0)
–5·3% 
(–5·6 to –5·1)
–5·1% 
(–5·6 to –4·6)
Luxembourg 19·7 
(9·6 to 28·9)
75·9 
(31·9 to 115)
95·6 
(41·5 to 141)
0·6 
(0·6 to 0·7)
1·8 
(1·7 to 1·9)
2·4 
(2·3 to 2·5)
–3·7% 
(–5·6 to –2·3)
2·5% 
(–4·8 to 5·9)
–4·8% 
(–5·2 to –4·3)
–4·8% 
(–5·5 to –4·2)
Malta 16·7 
(9·1 to 23·9)
81·7 
(43·7 to 133)
98·4 
(53·3 to 155)
0·4 
(0·4 to 0·5)
1·2 
(1·1 to 1·3)
1·6 
(1·6 to 1·7)
3·7% 
(1·6 to 5·1)
9·1% 
(7·7 to 10·2)
–2·1% 
(–2·5 to –1·8)
–2·7% 
(–3·4 to –2·0)
Netherlands 187 
(95·1 to 283)
344 
(166 to 526)
531 
(260 to 804)
17·1 
(16·1 to 18·1)
38·5 
(36·5 to 40·7)
55·5 
(53·3 to 58·0)
3·9% 
(2·5 to 5·2)
–7·3% 
(–13·2 to –3·3)
–8·5% 
(–8·8 to –8·2)
–4·7% 
(–5·3 to –4·2)
Norway 95·3 
(50·8 to 141)
197 
(99·0 to 300)
292 
(150 to 441)
4·3 
(4·2 to 4·4)
10·5 
(10·2 to 10·7)
14·8 
(14·5 to 15·1)
–1·0% 
(–3·4 to 0·9)
0·7% 
(–2·8 to 3·6)
–5·2% 
(–5·4 to –5·0)
–1·0% 
(–1·3 to –0·8)
Portugal 1550 
(776 to 2320)
6080 
(2930 to 9150)
7630 
(3730 to 11 200)
108 
(102 to 115)
394 
(372 to 418)
502 
(479 to 528)
2·5% 
(–0·5 to 5·3)
2·5% 
(–2·1 to 6·1)
7·9% 
(7·6 to 8·2)
–6·2% 
(–6·8 to –5·7)
Spain 1150 
(464 to 2120)
5380 
(2160 to 
9960)
6530 
(2820 to 11 800)
146 
(136 to 157)
563 
(531 to 598)
708 
(675 to 743)
–10·3% 
(–12·1 to –8·6)
5·8% 
(1·8 to 8·4)
–4·7% 
(–5·0 to –4·5)
–7·3% 
(–7·9 to –6·8)
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Sweden 243 
(109 to 379)
383 
(185 to 593)
626 
(305 to 962)
8·2 
(7·8 to 8·6)
14·6 
(14·0 to 15·1)
22·8 
(22·1 to 23·4)
–5·1% 
(–7·3 to –3·5)
1·5% 
(–3·9 to 3·6)
–4·6% 
(–4·8 to –4·3)
–5·3% 
(–5·7 to –5·0)
Switzerland 194 
(74·5 to 288)
460 
(152 to 704)
654 
(226 to 987)
10·5 
(9·9 to 11·1)
27·9 
(26·4 to 29·6)
38·3 
(36·7 to 40·2)
–7·0% 
(–9·3 to –4·0)
–0·1% 
(–6·7 to 2·1)
–7·0% 
(–7·4 to –6·6)
–6·4% 
(–7·0 to –5·8)
UK 1950 
(1120 to 2800)
5200 
(3010 to 7410)
7150 
(4110 to 10 100)
89·2 
(88·5 to 89·9)
175 
(174 to 176)
264 
(263 to 266)
3·7% 
(1·7 to 5·1)
1·1% 
(–0·8 to 2·5)
–2·4% 
(–2·5 to –2·4)
–3·9% 
(–3·9 to –3·8)
Latin America 
and Caribbean
52 200 
(44 900 to 
60 600)
110 000 
(94 300 to 
129 000)
162 000 
(140 000 to 
188 000)
14 100 
(12 800 to 
16 400)
28 400 
(26 700 to 
31 100)
42 500 
(39 800 to 
47 300)
–0·5% 
(–1·8 to 0·6)
2·1% 
(0·6 to 3·2)
4·1% 
(3·3 to 4·5)
–2·9% 
(–3·4 to –2·1)
Andean Latin 
America
3950 
(2520 to 
6980)
8440 
(5850 to 
13 200)
12 400 
(8420 to 
19 800)
1600 
(803 to 3610)
3060 
(1830 to 
5640)
4660 
(2630 to 
9190)
5·6% 
(1·5 to 8·4)
2·0% 
(–0·2 to 4·5)
6·6% 
(3·1 to 9·6)
0·9% 
(–2·8 to 4·6)
Bolivia 905 
(77·5 to 3880)
1590 
(168 to 5750)
2490 
(260 to 9880)
458 
(11·3 to 2490)
709 
(31·3 to 3220)
1170 
(46·3 to 5690)
0·2% 
(–10·4 to 8·7)
2·3% 
(–4·8 to 7·0)
4·0% 
(–4·3 to 15·5)
0·5% 
(–20·2 to 7·9)
Ecuador 1050 
(708 to 1410)
2060 
(1740 to 2580)
3100 
(2500 to 3980)
271 
(252 to 293)
822 
(775 to 874)
1090 
(1040 to 1150)
9·2% 
(4·5 to 12·0)
1·4% 
(0·2 to 2·6)
11·9% 
(11·6 to 12·2)
0·4% 
(–0·2 to 1·0)
Peru 1990 
(1390 to 3030)
4790 
(3320 to 7700)
6780 
(4730 to 10 600)
868 
(430 to 1320)
1530 
(830 to 2370)
2400 
(1270 to 3710)
7·1% 
(5·1 to 8·4)
2·0% 
(–0·9 to 5·7)
6·4% 
(5·0 to 7·9)
1·1% 
(–3·7 to 4·0)
Caribbean 8830 
(6730 to 
11 000)
9990 
(8020 to 
12 200)
18 800 
(15 600 to 
22 300)
3460 
(2670 to 
4410)
5100 
(4300 to 
6200)
8560 
(7470 to 
9950)
–4·4% 
(–5·8 to –2·9)
–2·5% 
(–4·1 to –0·9)
6·5% 
(4·1 to 8·1)
–7·5% 
(–8·4 to –6·6)
Antigua and 
Barbuda
2·6 
(2·1 to 3·4)
6·3 
(5·3 to 8·2)
8·9 
(7·5 to 11·6)
2·3 
(2·2 to 2·3)
5·2 
(5·1 to 5·4)
7·5 
(7·4 to 7·6)
–6·8% 
(–8·4 to –5·6)
2·7% 
(0·4 to 5·8)
–2·6% 
(–2·8 to –2·5)
–0·8% 
(–1·1 to –0·6)
The Bahamas 137 
(115 to 186)
227 
(186 to 286)
365 
(321 to 463)
47·2 
(46·1 to 48·5)
67·0 
(65·3 to 68·8)
114 
(112 to 116)
–3·2% 
(–4·2 to –1·9)
3·4% 
(2·4 to 5·0)
1·8% 
(1·6 to 2·0)
–3·0% 
(–3·3 to –2·8)
Barbados 26·1 
(18·7 to 37·2)
43·2 
(30·3 to 61·5)
69·3 
(49·6 to 98·4)
8·8 
(8·6 to 8·9)
16·2 
(15·9 to 16·6)
25·0 
(24·6 to 25·4)
–1·5% 
(–2·6 to 1·0)
–0·6% 
(–4·0 to 3·2)
–1·9% 
(–2·1 to –1·8)
–3·6% 
(–3·9 to –3·4)
Belize 113 
(86·6 to 148)
138 
(122 to 167)
251 
(210 to 313)
28·6 
(27·9 to 29·3)
52·6 
(51·2 to 53·9)
81·2 
(79·5 to 82·6)
0·3% 
(–1·0 to 1·8)
3·7% 
(2·5 to 5·2)
0·3% 
(0·1 to 0·5)
–1·1% 
(–1·4 to –0·9)
Bermuda 1·4 
(1·2 to 1·6)
4·4 
(3·9 to 5·0)
5·8 
(5·1 to 6·6)
1·6 
(1·5 to 1·6)
5·3 
(5·2 to 5·4)
6·8 
(6·7 to 7·0)
–8·3% 
(–9·5 to –7·5)
1·0% 
(–0·8 to 3·4)
–4·6% 
(–4·7 to –4·4)
–2·0% 
(–2·3 to –1·7)
Cuba 684 
(295 to 1180)
2130 
(1140 to 3350)
2810 
(1540 to 4330)
58·6 
(57·3 to 60·0)
303 
(295 to 310)
361 
(354 to 369)
11·5% 
(9·8 to 13·1)
5·8% 
(4·1 to 7·3)
4·5% 
(4·4 to 4·7)
7·7% 
(7·5 to 8·0)
Dominica 2·0 
(1·4 to 3·2)
4·7 
(3·8 to 6·2)
6·6 
(5·3 to 9·4)
1·2 
(1·2 to 1·2)
3·9 
(3·8 to 3·9)
5·0 
(4·9 to 5·1)
–5·3% 
(–6·4 to –4·4)
1·8% 
(–0·1 to 4·4)
–1·4% 
(–1·6 to –1·2)
–1·0% 
(–1·3 to –0·7)
Dominican 
Republic
1740 
(787 to 2930)
2220 
(1210 to 
3600)
3960 
(2410 to 6000)
853 
(332 to 1510)
1710 
(1140 to 2520)
2560 
(1800 to 
3630)
0·2% 
(–2·4 to 3·0)
–3·1% 
(–5·7 to –0·5)
21·5% 
(17·9 to 24·9)
–6·2% 
(–8·1 to –4·5)
Grenada 1·9 
(1·4 to 2·6)
4·6 
(4·0 to 5·7)
6·5 
(5·5 to 8·2)
1·7 
(1·6 to 1·7)
4·5 
(4·4 to 4·6)
6·2 
(6·0 to 6·3)
–6·2% 
(–7·6 to –5·0)
–0·1% 
(–1·8 to 2·1)
–2·8% 
(–3·0 to –2·7)
–0·8% 
(–1·1 to –0·5)
Guyana 335 
(236 to 426)
265 
(190 to 354)
600 
(431 to 756)
79·4 
(77·6 to 81·2)
116 
(113 to 120)
196 
(192 to 199)
5·0% 
(1·2 to 8·1)
–4·2% 
(–5·7 to –2·3)
5·9% 
(5·7 to 6·0)
–3·4% 
(–3·7 to –3·2)
Haiti 4590 
(2990 to 
6280)
3320 
(2170 to 
4910)
7910 
(5770 to 10 500)
1860 
(1290 to 
2550)
1990 
(1570 to 2720)
3850 
(3150 to 
4870)
–8·5% 
(–10·1 to –6·5)
–6·1% 
(–8·3 to –4·2)
6·4% 
(2·5 to 9·7)
–12·6% 
(–14·0 to –11·2)
Jamaica 529 
(369 to 759)
751 
(590 to 968)
1280 
(965 to 1700)
187 
(182 to 191)
253 
(247 to 259)
440 
(432 to 447)
–0·5% 
(–5·6 to 2·9)
1·2% 
(–1·6 to 3·7)
3·3% 
(3·2 to 3·5)
–2·4% 
(–2·6 to –2·1)
Puerto Rico 53·7 
(45·2 to 62·8)
144 
(118 to 171)
198 
(165 to 231)
66·8 
(65·3 to 68·4)
171 
(167 to 176)
238 
(234 to 243)
–14·6% 
(–16·0 to –13·7)
2·8% 
(1·1 to 5·0)
–5·7% 
(–5·8 to –5·5)
–5·9% 
(–6·2 to –5·6)
Saint Lucia 3·4 
(2·7 to 4·8)
5·4 
(4·5 to 7·1)
8·8 
(7·3 to 11·7)
2·9 
(2·8 to 3·0)
4·9 
(4·8 to 5·1)
7·8 
(7·7 to 8·0)
–6·8% 
(–8·1 to –5·7)
1·6% 
(–0·5 to 4·3)
–2·2% 
(–2·3 to –2·0)
–2·5% 
(–2·7 to –2·2)
Saint Vincent 
and the 
Grenadines
7·2 
(5·9 to 9·7)
13·7 
(11·6 to 17·5)
20·9 
(17·6 to 27·0)
6·8 
(6·6 to 7·0)
13·3 
(13·0 to 13·7)
20·1 
(19·8 to 20·5)
–6·2% 
(–8·1 to –4·4)
1·2% 
(–0·7 to 3·8)
0·8% 
(0·7 to 1·0)
–2·3% 
(–2·5 to –2·0)
Suriname 93·8 
(74·7 to 127)
114 
(91·2 to 148)
207 
(169 to 271)
40·2 
(39·3 to 41·2)
61·6 
(60·0 to 63·1)
102 
(99·9 to 104)
–0·7% 
(–4·6 to 3·7)
0·2% 
(–1·9 to 3·1)
1·9% 
(1·8 to 2·1)
–3·9% 
(–4·1 to –3·6)
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Trinidad and 
Tobago
187 
(151 to 250)
227 
(192 to 280)
414 
(354 to 512)
83·8 
(81·6 to 85·9)
136 
(132 to 139)
219 
(216 to 224)
–1·0% 
(–2·9 to 1·5)
–1·1% 
(–2·7 to 0·9)
4·3% 
(4·2 to 4·5)
–2·3% 
(–2·6 to –2·1)
Virgin Islands 3·9 
(2·8 to 5·9)
10·7 
(7·2 to 17·0)
14·7 
(10·1 to 22·8)
3·0 
(2·9 to 3·0)
6·0 
(5·8 to 6·2)
9·0 
(8·8 to 9·1)
–4·1% 
(–8·2 to –1·5)
4·4% 
(1·4 to 7·4)
0·3% 
(0·1 to 0·4)
–0·6% 
(–0·9 to –0·4)
Central Latin 
America
10 500 
(7800 to 
14 100)
35 300 
(27 800 to 
45 900)
45 800 
(35 700 to 
58 900)
3330 
(3140 to 
3480)
9770 
(9420 to 
10 100)
13 100 
(12 600 to 
13 500)
–0·9% 
(–2·4 to 0·6)
2·7% 
(1·0 to 4·2)
4·6% 
(4·5 to 4·8)
–1·8% 
(–2·2 to –1·6)
Colombia 2430 
(1640 to 
3480)
7090 
(5400 to 
9580)
9520 
(7040 to 
12 900)
661 
(627 to 697)
1980 
(1890 to 
2070)
2640 
(2530 to 
2740)
2·9% 
(0·4 to 5·4)
5·0% 
(2·4 to 7·6)
8·4% 
(8·1 to 8·7)
–2·3% 
(–2·8 to –1·9)
Costa Rica 91·4 
(62·4 to 121)
295 
(217 to 406)
386 
(283 to 526)
38·5 
(36·5 to 40·6)
115 
(108 to 122)
153 
(146 to 160)
0·9% 
(0·1 to 1·9)
–1·5% 
(–3·9 to 0·3)
2·2% 
(1·9 to 2·6)
–0·4% 
(–0·9 to 0·2)
El Salvador 458 
(276 to 660)
789 
(487 to 1080)
1250 
(770 to 1690)
247 
(86·2 to 378)
481 
(235 to 685)
728 
(320 to 1050)
7·1% 
(3·0 to 10·5)
–4·9% 
(–7·7 to –2·4)
11·5% 
(9·9 to 12·9)
–1·0% 
(–6·9 to 1·3)
Guatemala 830 
(375 to 1910)
1480 
(709 to 3230)
2310 
(1100 to 5120)
228 
(217 to 240)
472 
(449 to 496)
700 
(676 to 727)
2·7% 
(–2·8 to 6·8)
–1·2% 
(–6·9 to 3·7)
3·2% 
(2·9 to 3·5)
–5·4% 
(–5·9 to –5·0)
Honduras 211 
(127 to 334)
268 
(179 to 393)
479 
(320 to 683)
25·4 
(17·4 to 39·1)
37·5 
(29·1 to 47·8)
62·9 
(47·0 to 83·2)
0·5% 
(–1·9 to 2·7)
–3·0% 
(–7·1 to 0·3)
–0·9% 
(–3·2 to 3·2)
–8·2% 
(–11·8 to –4·8)
Mexico 3930 
(2930 to 
5560)
15 900 
(11 700 to 
21 400)
19 800 
(14 600 to 
26 000)
1250 
(1230 to 
1260)
4330 
(4270 to 
4380)
5580 
(5520 to 
5630)
–3·8% 
(–5·2 to –2·4)
2·8% 
(0·7 to 4·8)
3·7% 
(3·6 to 3·8)
–2·4% 
(–2·5 to –2·2)
Nicaragua 718 
(490 to 1030)
1240 
(794 to 1750)
1960 
(1320 to 2680)
195 
(103 to 275)
395 
(229 to 582)
590 
(333 to 835)
14·3% 
(10·7 to 16·5)
6·1% 
(3·1 to 9·1)
11·3% 
(9·8 to 12·8)
9·5% 
(4·6 to 13·4)
Panama 426 
(338 to 538)
1440 
(1120 to 2000)
1870 
(1490 to 2510)
128 
(121 to 135)
398 
(377 to 420)
526 
(505 to 548)
–1·0% 
(–2·2 to 0·8)
4·8% 
(3·3 to 6·5)
3·4% 
(3·0 to 3·8)
–1·0% 
(–1·6 to –0·5)
Venezuela 1370 
(979 to 1930)
6830 
(5480 to 8270)
8200 
(6490 to 10 100)
557 
(522 to 593)
1570 
(1480 to 1670)
2130 
(2030 to 2230)
3·9% 
(3·0 to 5·2)
2·8% 
(0·9 to 4·5)
3·1% 
(2·9 to 3·3)
–0·1% 
(–0·7 to 0·4)
Tropical Latin 
America
29 000 
(20 800 to 
35 000)
56 000 
(41 500 to 
66 700)
85 000 
(62 600 to 
101 000)
5720 
(5530 to 
5880)
10 500 
(10 200 to 
10 700)
16 200 
(15 700 to 
16 500)
2·7% 
(1·2 to 4·0)
3·4% 
(1·8 to 4·2)
1·7% 
(1·6 to 1·9)
–0·9% 
(–1·2 to –0·7)
Brazil 28 400 
(20 400 to 
34 300)
55 000 
(40 700 to 
65 400)
83 300 
(61 500 to 
99 100)
5430 
(5330 to 
5540)
9970 
(9800 to 
10 100)
15 400 
(15 200 to 
15 600)
2·6% 
(1·1 to 3·9)
3·5% 
(1·9 to 4·3)
1·6% 
(1·5 to 1·7)
–1·2% 
(–1·4 to –1·0)
Paraguay 638 
(412 to 896)
1000 
(648 to 1350)
1640 
(1070 to 2220)
283 
(140 to 397)
478 
(261 to 666)
762 
(412 to 1060)
11·8% 
(4·3 to 16·4)
–0·1% 
(–2·7 to 2·4)
11·9% 
(9·5 to 16·0)
5·4% 
(1·2 to 8·7)
North Africa 
and Middle 
East
8300 
(4650 to 
15 300)
9240 
(5490 to 
18 900)
17 500 
(10 700 to 
32 500)
4690 
(3410 to 
6700)
4750 
(3380 to 
7020)
9440 
(7180 to 
13 100)
4·2% 
(1·4 to 7·7)
–0·4% 
(–4·0 to 3·0)
10·5% 
(8·1 to 12·7)
0·5% 
(–1·6 to 2·4)
Afghanistan 353 
(12·2 to 1650)
569 
(26·6 to 2360)
922 
(41·7 to 3660)
108 
(1·3 to 592)
194 
(3·4 to 961)
302 
(5·7 to 1450)
2·0% 
(–8·6 to 12·2)
8·4% 
(–2·2 to 16·0)
4·3% 
(–4·5 to 14·9)
2·6% 
(–21·8 to 11·3)
Algeria 396 
(4·8 to 1800)
505 
(6·2 to 1970)
901 
(11·1 to 3490)
130 
(8·6 to 988)
197 
(7·2 to 939)
327 
(14·9 to 1860)
8·7% 
(2·3 to 14·1)
–1·0% 
(–42·9 to 7·8)
8·9% 
(1·7 to 13·1)
–2·2% 
(–17·4 to 4·7)
Bahrain 4·6 
(3·8 to 5·9)
15·5 
(13·2 to 18·4)
20·2 
(17·3 to 23·9)
3·0 
(2·4 to 3·7)
8·5 
(7·4 to 10·0)
11·5 
(9·8 to 13·6)
–4·3% 
(–6·1 to –2·7)
–0·6% 
(–1·9 to 1·0)
1·8% 
(0·9 to 3·1)
–6·4% 
(–7·5 to –5·4)
Egypt 154 
(111 to 223)
403 
(261 to 552)
557 
(394 to 723)
22·5 
(14·3 to 39·9)
42·3 
(28·7 to 62·7)
64·8 
(45·6 to 92·3)
0·6% 
(–1·7 to 2·7)
6·8% 
(3·5 to 9·3)
1·3% 
(–0·6 to 4·6)
–7·2% 
(–10·2 to –3·6)
Iran 1540 
(937 to 2200)
1610 
(1110 to 2270)
3150 
(2130 to 4190)
322 
(273 to 371)
470 
(428 to 521)
792 
(707 to 889)
8·7% 
(1·1 to 14·5)
10·3% 
(6·7 to 12·5)
10·2% 
(9·3 to 11·4)
5·3% 
(4·2 to 6·4)
Iraq 124 
(61·7 to 241)
104 
(52·3 to 201)
229 
(115 to 443)
60·6 
(41·0 to 94·3)
55·1 
(36·1 to 86·5)
116 
(77·9 to 181)
4·9% 
(0·4 to 8·1)
5·0% 
(0·6 to 9·1)
9·3% 
(6·6 to 11·6)
2·7% 
(–1·0 to 5·9)
Jordan 18·5 
(12·3 to 26·7)
35·2 
(23·9 to 47·1)
53·7 
(37·1 to 69·7)
8·5 
(7·1 to 9·9)
14·5 
(9·1 to 20·7)
22·9 
(16·9 to 29·7)
5·8% 
(2·8 to 8·2)
1·1% 
(–2·1 to 3·7)
6·9% 
(6·0 to 8·1)
2·6% 
(–1·5 to 5·4)
Kuwait 4·8 
(4·0 to 6·4)
10·6 
(7·9 to 13·5)
15·4 
(12·3 to 19·2)
2·9 
(2·4 to 3·4)
2·5 
(2·3 to 2·8)
5·4 
(4·9 to 6·0)
–3·1% 
(–5·0 to –1·7)
1·4% 
(–1·3 to 4·0)
–2·2% 
(–3·0 to –1·3)
–5·1% 
(–6·6 to –3·4)
Lebanon 92·2 
(4·0 to 403)
162 
(8·5 to 802)
254 
(13·1 to 1090)
48·6 
(0·8 to 210)
63·9 
(2·1 to 368)
113 
(3·3 to 578)
–2·4% 
(–11·3 to 5·4)
3·7% 
(–6·8 to 11·7)
–0·6% 
(–10·4 to 5·5)
–1·2% 
(–13·0 to 8·4)
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Libya 95·0 
(4·8 to 421)
93·9 
(5·1 to 479)
189 
(10·9 to 845)
47·3 
(3·5 to 201)
56·0 
(4·2 to 261)
103 
(8·8 to 436)
5·4% 
(–4·9 to 14·2)
5·2% 
(–5·5 to 13·1)
9·1% 
(0·9 to 16·7)
3·2% 
(–5·7 to 10·4)
Morocco 557 
(28·7 to 2580)
551 
(28·5 to 2790)
1110 
(59·0 to 4860)
246 
(6·2 to 1740)
356 
(8·4 to 2260)
602 
(16·0 to 3660)
5·8% 
(–4·3 to 13·6)
–4·0% 
(–15·1 to 3·9)
10·7% 
(–0·8 to 17·5)
–4·6% 
(–19·4 to 2·6)
Oman 54·4 
(30·7 to 79·9)
541 
(241 to 1040)
595 
(273 to 1120)
11·4 
(5·8 to 19·2)
123 
(62·3 to 181)
135 
(70·0 to 199)
9·8% 
(7·1 to 11·5)
4·3% 
(–2·1 to 8·4)
9·9% 
(8·6 to 11·1)
7·3% 
(0·1 to 10·1)
Palestine 9·2 
(5·7 to 14·5)
10·8 
(7·0 to 16·3)
20·0 
(12·7 to 30·8)
4·6 
(3·8 to 5·5)
5·7 
(4·8 to 6·7)
10·3 
(8·6 to 12·1)
4·2% 
(2·5 to 5·5)
2·3% 
(–0·3 to 4·5)
9·9% 
(8·8 to 11·4)
0·7% 
(–0·5 to 1·9)
Qatar 2·4 
(1·8 to 3·1)
8·1 
(6·4 to 10·5)
10·5 
(8·5 to 13·3)
2·2 
(1·5 to 2·9)
4·7 
(4·1 to 5·7)
7·0 
(5·8 to 8·1)
–8·0% 
(–9·6 to –6·5)
–2·4% 
(–3·9 to –0·7)
–2·4% 
(–3·8 to –1·0)
–5·0% 
(–6·3 to –2·9)
Saudi Arabia 331 
(187 to 706)
342 
(198 to 652)
673 
(397 to 1270)
245 
(191 to 324)
281 
(209 to 353)
526 
(402 to 676)
1·0% 
(–3·6 to 4·2)
–0·2% 
(–4·0 to 5·2)
6·4% 
(4·0 to 8·5)
–1·4% 
(–4·5 to 0·8)
Sudan 3760 
(1610 to 7140)
2810 
(1410 to 
5420)
6570 
(3440 to 
12 200)
3110 
(2130 to 
4230)
2190 
(1650 to 
3010)
5300 
(4150 to 
6740)
3·7% 
(0·7 to 8·7)
–5·7% 
(–11·3 to –0·3)
15·6% 
(12·3 to 18·0)
0·3% 
(–1·4 to 2·0)
Syria 11·0 
(7·2 to 16·8)
30·8 
(16·5 to 52·2)
41·8 
(28·7 to 62·9)
6·6 
(4·8 to 9·7)
4·7 
(3·2 to 8·1)
11·3 
(8·2 to 17·7)
2·6% 
(–0·1 to 4·2)
1·6% 
(–1·1 to 5·7)
3·7% 
(2·2 to 4·7)
–4·1% 
(–7·0 to –0·1)
Tunisia 180 
(19·3 to 750)
251 
(26·5 to 905)
431 
(50·0 to 1630)
80·4 
(2·4 to 392)
113 
(2·8 to 455)
194 
(5·4 to 790)
9·8% 
(2·6 to 17·1)
4·3% 
(–4·4 to 11·1)
11·0% 
(2·9 to 16·5)
5·9% 
(–8·0 to 11·4)
Turkey 171 
(114 to 255)
303 
(203 to 438)
474 
(325 to 689)
70·6 
(55·8 to 85·2)
130 
(102 to 156)
200 
(159 to 236)
12·3% 
(6·9 to 50·5)
1·5% 
(–1·1 to 3·5)
13·5% 
(9·0 to 43·3)
6·5% 
(3·3 to 9·1)
United Arab 
Emirates
42·0 
(2·1 to 191)
195 
(8·7 to 1210)
237 
(11·2 to 1290)
23·5 
(1·9 to 98·8)
181 
(11·0 to 967)
205 
(12·5 to 1020)
11·2% 
(–3·9 to 22·2)
1·8% 
(–9·9 to 12·3)
10·2% 
(1·3 to 18·2)
20·3% 
(–5·0 to 34·3)
Yemen 393 
(13·5 to 1820)
689 
(25·9 to 3110)
1080 
(43·2 to 4940)
135 
(1·9 to 699)
252 
(4·7 to 1320)
387 
(7·3 to 1940)
1·6% 
(–9·9 to 13·9)
5·5% 
(–7·6 to 13·7)
3·9% 
(–5·5 to 16·3)
–0·0% 
(–22·1 to 9·6)
South Asia 49 900 
(29 500 to 
82 500)
67 700 
(39 100 to 
116 000)
118 000 
(69 100 to 
195 000)
26 200 
(22 500 to 
35 100)
34 500 
(28 300 to 
51 000)
60 700 
(51 400 to 
84 900)
6·1% 
(1·1 to 11·6)
–1·8% 
(–5·4 to 2·1)
30·2% 
(23·9 to 35·9)
–12·4% 
(–14·0 to –9·4)
Bangladesh 414 
(6·6 to 1980)
542 
(15·9 to 2330)
956 
(21·7 to 4120)
266 
(0·8 to 1520)
361 
(1·8 to 1850)
627 
(2·4 to 3170)
52·2% 
(31·4 to 60·7)
–1·8% 
(–11·7 to 8·9)
43·8% 
(19·6 to 53·6)
8·8% 
(–11·1 to 18·6)
Bhutan 41·0 
(0·7 to 186)
94·2 
(2·6 to 420)
135 
(3·3 to 597)
24·1 
(0·1 to 122)
57·2 
(1·2 to 254)
81·3 
(1·4 to 363)
3·9% 
(–10·9 to 19·1)
1·6% 
(–8·1 to 11·1)
8·9% 
(–2·9 to 22·1)
4·9% 
(–7·7 to 16·5)
India 43 600 
(27 600 to 
65 800)
55 800 
(34 600 to 
82 900)
99 400 
(62 900 to 
148 000)
23 400 
(21 800 to 
25 100)
28 700 
(27 100 to 
30 500)
52 100 
(49 200 to 
55 400)
5·9% 
(1·1 to 11·4)
–2·3% 
(–5·7 to 1·8)
34·0% 
(30·3 to 37·4)
–13·6% 
(–14·3 to –12·9)
Nepal 824 
(12·9 to 3920)
1420 
(37·3 to 6520)
2240 
(52·3 to 9930)
762 
(3·4 to 4880)
1860 
(12·8 to 9710)
2620 
(17·3 to 
13 500)
30·1% 
(16·4 to 44·9)
–11·1% 
(–21·4 to –1·3)
65·3% 
(52·9 to 81·6)
–2·2% 
(–19·4 to 6·0)
Pakistan 4990 
(81·4 to 
21 300)
9930 
(306 to 
42 500)
14 900 
(445 to 62 900)
1780 
(7·5 to 9830)
3530 
(23·1 to 
16 500)
5310 
(31·3 to 
25 900)
6·3% 
(–7·3 to 21·3)
7·8% 
(–1·7 to 18·8)
4·4% 
(–7·9 to 18·3)
12·9% 
(–11·2 to 25·5)
Southeast 
Asia, east Asia, 
and Oceania
39 200 
(30 600 to 
50 500)
92 200 
(69 600 to 
127 000)
131 000 
(103 000 to 
175 000)
26 600 
(22 900 to 
32 800)
62 400 
(58 300 to 
68 100)
89 000 
(81 900 to 
99 600)
1·8% 
(0·3 to 3·8)
–3·2% 
(–4·9 to –1·5)
13·5% 
(12·6 to 14·8)
–0·6% 
(–1·8 to 0·5)
East Asia 7320 
(3270 to 
12 800)
28 000 
(11 300 to 
48 800)
35 300 
(14 500 to 
61 500)
9070 
(8330 to 
10 400)
27 400 
(25 400 to 
30 500)
36 500 
(33 800 to 
40 900)
9·3% 
(5·8 to 11·9)
–7·0% 
(–13·3 to –4·6)
8·6% 
(7·3 to 10·3)
4·7% 
(3·9 to 5·3)
China 6860 
(3020 to 
11 400)
26 500 
(10 900 to 
45 900)
33 300 
(13 800 to 
57 300)
8640 
(8080 to 
9140)
26 200 
(24 500 to 
27 600)
34 800 
(32 600 to 
36 600)
9·2% 
(5·5 to 11·9)
–7·2% 
(–13·3 to –4·9)
8·5% 
(7·3 to 10·2)
4·7% 
(3·9 to 5·2)
North Korea 321 
(2·4 to 1970)
869 
(6·6 to 5270)
1190 
(9·4 to 7690)
263 
(3·1 to 1460)
634 
(9·2 to 3590)
897 
(13·6 to 5260)
11·0% 
(–0·2 to 27·3)
–1·6% 
(–16·8 to 8·3)
14·5% 
(1·9 to 40·9)
5·7% 
(–2·6 to 15·8)
Taiwan 
(province of 
China)
21·7 
(10·1 to 35·8)
189 
(94·4 to 340)
210 
(106 to 378)
21·8 
(19·8 to 23·9)
176 
(161 to 193)
198 
(182 to 215)
8·8% 
(5·3 to 11·8)
–7·8% 
(–13·5 to –5·2)
7·0% 
(6·4 to 7·5)
4·0% 
(3·0 to 5·1)
Oceania 1980 
(247 to 7710)
1550 
(214 to 6120)
3530 
(461 to 13 200)
778 
(391 to 2400)
729 
(342 to 2050)
1510 
(747 to 4310)
18·8% 
(9·9 to 26·3)
–4·7% 
(–16·2 to 2·1)
27·4% 
(21·1 to 33·9)
–7·9% 
(–11·8 to –3·6)
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American 
Samoa
0·2 
(0·1 to 0·4)
0·5 
(0·3 to 0·8)
0·7 
(0·4 to 1·1)
0·1 
(0·1 to 0·1)
0·2 
(0·2 to 0·3)
0·3 
(0·3 to 0·4)
–1·8% 
(–8·6 to 4·5)
3·2% 
(–0·4 to 7·2)
7·0% 
(2·1 to 15·3)
0·6% 
(–1·8 to 2·8)
Federated 
States of 
Micronesia
34·5 
(0·2 to 235)
39·6 
(0·4 to 246)
74·1 
(0·6 to 434)
12·2 
(0·1 to 51·6)
18·3 
(0·3 to 83·6)
30·4 
(0·5 to 131)
10·2% 
(–3·0 to 26·1)
7·3% 
(–7·3 to 18·0)
9·5% 
(–1·5 to 27·8)
12·7% 
(2·5 to 25·8)
Fiji 24·8 
(18·1 to 34·7)
22·1 
(16·2 to 30·7)
46·9 
(35·9 to 64·6)
5·5 
(3·5 to 9·6)
4·9 
(3·0 to 8·3)
10·4 
(7·0 to 18·1)
2·5% 
(–3·9 to 7·4)
4·3% 
(2·8 to 6·0)
8·9% 
(5·8 to 14·1)
–3·2% 
(–6·1 to 1·4)
Guam 0·8 
(0·4 to 1·4)
6·7 
(3·8 to 11·3)
7·5 
(4·2 to 12·6)
0·6 
(0·4 to 0·8)
3·7 
(2·9 to 4·7)
4·3 
(3·3 to 5·5)
–3·6% 
(–10·8 to 2·9)
4·0% 
(0·4 to 7·8)
5·0% 
(–0·0 to 13·9)
0·6% 
(–1·9 to 2·5)
Kiribati 0·3 
(0·2 to 0·7)
0·4 
(0·2 to 0·6)
0·7 
(0·4 to 1·3)
0·2 
(0·2 to 0·3)
0·3 
(0·2 to 0·3)
0·5 
(0·4 to 0·6)
–6·6% 
(–8·0 to –5·0)
0·9% 
(–3·5 to 6·5)
1·3% 
(–1·3 to 4·1)
–3·5% 
(–4·3 to –2·6)
Marshall 
Islands
3·9 
(0·0 to 24·5)
3·8 
(0·0 to 26·8)
7·7 
(0·1 to 50·4)
1·4 
(0·0 to 7·9)
1·3 
(0·0 to 8·2)
2·7 
(0·0 to 15·8)
0·1% 
(–11·7 to 15·0)
7·9% 
(–5·4 to 16·2)
5·8% 
(–4·2 to 20·9)
4·2% 
(–7·5 to 16·3)
Northern 
Mariana 
Islands
0·2 
(0·1 to 0·3)
0·6 
(0·3 to 0·9)
0·7 
(0·4 to 1·2)
0·1 
(0·1 to 0·2)
0·3 
(0·2 to 0·4)
0·4 
(0·3 to 0·5)
–0·0% 
(–6·6 to 5·8)
3·9% 
(0·5 to 7·5)
8·5% 
(4·0 to 16·3)
1·0% 
(–1·2 to 3·3)
Papua New 
Guinea
1730 
(155 to 7240)
1320 
(108 to 5660)
3050 
(268 to 12 000)
688 
(339 to 2200)
636 
(285 to 1880)
1320 
(627 to 4030)
25·2% 
(19·0 to 34·9)
–5·9% 
(–19·4 to 1·3)
48·6% 
(40·7 to 65·2)
–9·1% 
(–13·0 to –4·4)
Samoa 13·2 
(0·1 to 85·8)
13·2 
(0·1 to 95·2)
26·4 
(0·3 to 172)
4·6 
(0·1 to 25·7)
4·5 
(0·1 to 26·8)
9·1 
(0·1 to 55·5)
0·7% 
(–11·3 to 15·9)
8·1% 
(–5·0 to 16·3)
6·1% 
(–4·2 to 21·4)
4·6% 
(–6·7 to 17·0)
Solomon 
Islands
42·8 
(0·4 to 278)
37·0 
(0·4 to 268)
79·8 
(0·9 to 519)
15·1 
(0·2 to 91·6)
13·0 
(0·2 to 77·9)
28·1 
(0·4 to 166)
–0·1% 
(–12·2 to 14·5)
7·5% 
(–5·3 to 15·8)
5·9% 
(–4·0 to 20·8)
3·7% 
(–7·5 to 15·9)
Tonga 1·1 
(0·6 to 2·0)
1·5 
(0·8 to 2·5)
2·6 
(1·4 to 4·4)
0·5 
(0·4 to 0·6)
0·7 
(0·6 to 0·9)
1·2 
(0·9 to 1·6)
–0·2% 
(–7·0 to 5·8)
4·0% 
(0·5 to 8·1)
8·4% 
(3·7 to 16·3)
1·5% 
(–1·0 to 3·4)
Vanuatu 20·7 
(0·2 to 137)
17·7 
(0·2 to 123)
38·3 
(0·4 to 254)
7·0 
(0·1 to 39·1)
6·4 
(0·1 to 36·7)
13·4 
(0·2 to 78·5)
3·3% 
(–9·0 to 18·4)
2·4% 
(–19·4 to 15·7)
6·8% 
(–3·5 to 22·4)
4·0% 
(–5·8 to 16·0)
Southeast Asia 29 800 
(24 100 to 
38 400)
62 700 
(52 500 to 
81 000)
92 500 
(78 300 to 
116 000)
16 800 
(13 300 to 
22 800)
34 300 
(30 700 to 
38 900)
51 000 
(44 700 to 
60 300)
–1·5% 
(–4·2 to 1·6)
–2·2% 
(–3·8 to 0·5)
16·4% 
(15·0 to 18·0)
–3·4% 
(–5·5 to –1·7)
Cambodia 561 
(108 to 1390)
485 
(94·4 to 1230)
1050 
(208 to 2520)
502 
(303 to 893)
876 
(546 to 1380)
1380 
(884 to 1990)
2·3% 
(–3·8 to 9·6)
–10·4% 
(–23·8 to –2·7)
36·8% 
(32·1 to 42·2)
–15·2% 
(–18·6 to –11·4)
Indonesia 6480 
(5090 to 
8730)
11 300 
(8800 to 
15 600)
17 700 
(14 100 to 
24 100)
2500 
(2190 to 
3060)
4270 
(3850 to 
4870)
6770 
(6090 to 
7680)
5·8% 
(3·1 to 64·4)
3·2% 
(1·8 to 4·8)
32·1% 
(30·8 to 34·4)
6·9% 
(6·3 to 7·6)
Laos 223 
(1·6 to 1370)
579 
(6·0 to 3920)
802 
(8·0 to 5270)
138 
(0·3 to 1120)
388 
(1·2 to 2780)
526 
(1·5 to 4300)
25·4% 
(14·4 to 38·9)
–6·6% 
(–17·3 to 1·9)
56·2% 
(40·6 to 67·6)
1·6% 
(–14·3 to 10·0)
Malaysia 1200 
(904 to 1540)
3180 
(2060 to 3920)
4370 
(3010 to 5230)
615 
(328 to 844)
964 
(744 to 1270)
1580 
(1120 to 2070)
–0·7% 
(–3·5 to 2·3)
0·2% 
(–2·1 to 1·4)
19·4% 
(16·7 to 22·2)
–3·2% 
(–6·7 to –1·1)
Maldives 0·9 
(0·7 to 1·3)
0·3 
(0·2 to 0·4)
1·2 
(0·9 to 1·7)
0·6 
(0·6 to 0·7)
0·1 
(0·1 to 0·1)
0·8 
(0·7 to 0·8)
4·2% 
(1·8 to 6·9)
–2·3% 
(–4·9 to 0·3)
6·5% 
(4·8 to 8·4)
0·5% 
(–2·2 to 3·3)
Mauritius 104 
(71·7 to 140)
194 
(145 to 269)
298 
(233 to 382)
16·4 
(15·3 to 17·5)
79·4 
(73·9 to 85·3)
95·8 
(90·2 to 102)
20·9% 
(18·9 to 21·8)
3·1% 
(0·3 to 5·8)
6·5% 
(6·0 to 7·0)
5·3% 
(4·4 to 6·2)
Myanmar 4970 
(2730 to 7240)
4740 
(2970 to 
7960)
9710 
(7320 to 13 300)
2860 
(1640 to 
4270)
2490 
(2010 to 
3690)
5350 
(4330 to 
6700)
4·6% 
(3·0 to 6·0)
–7·3% 
(–8·4 to –6·2)
34·7% 
(31·7 to 37·7)
–12·6% 
(–14·4 to –10·4)
Philippines 3170 
(1880 to 
5090)
11 100 
(6600 to 
18 300)
14 300 
(8480 to 
23 200)
1390 
(1330 to 
1460)
2790 
(2650 to 
2930)
4180 
(4030 to 
4340)
0·0% 
(–8·4 to 9·3)
5·1% 
(1·6 to 8·6)
6·5% 
(6·3 to 6·7)
–3·1% 
(–3·5 to –2·7)
Sri Lanka 101 
(63·8 to 153)
190 
(103 to 289)
291 
(171 to 432)
25·2 
(17·0 to 35·6)
30·6 
(19·9 to 46·5)
55·8 
(37·4 to 81·6)
–0·6% 
(–9·6 to 10·8)
7·8% 
(2·3 to 11·9)
4·3% 
(1·8 to 8·8)
–4·1% 
(–8·4 to –0·0)
Seychelles 2·4 
(1·9 to 3·3)
3·4 
(2·6 to 4·8)
5·8 
(4·5 to 8·1)
2·4 
(2·2 to 2·7)
3·4 
(3·1 to 3·9)
5·8 
(5·3 to 6·5)
–5·1% 
(–6·3 to –3·7)
–1·4% 
(–3·3 to 0·3)
12·5% 
(9·1 to 15·3)
–0·3% 
(–1·0 to 0·4)
Thailand 9550 
(6490 to 
15 600)
15 000 
(12 300 to 
20 900)
24 500 
(19 300 to 
34 300)
7660 
(4790 to 
13 900)
11 700 
(9750 to 
14 500)
19 400 
(14 900 to 
27 600)
–5·3% 
(–10·1 to –1·4)
–3·6% 
(–6·0 to 2·2)
14·6% 
(12·1 to 18·1)
–1·5% 
(–6·4 to 2·3)
Timor-Leste 97·3 
(0·9 to 580)
153 
(1·8 to 1000)
250 
(2·8 to 1540)
90·9 
(1·0 to 500)
132 
(2·5 to 756)
223 
(3·8 to 1280)
–8·1% 
(–19·3 to 5·1)
–4·4% 
(–14·7 to 3·7)
15·1% 
(7·5 to 26·8)
–1·9% 
(–11·0 to 7·6)
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of change in 
new infections
Annualised rate of change in 
HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–17
(Continued from previous page)
Vietnam 3360 
(2330 to 
6080)
15 700 
(12 700 to 
21 000)
19 100 
(15 200 to 
25 900)
933 
(458 to 
2630)
10 500 
(8570 to 
13 100)
11 400 
(9060 to 
15 200)
5·8% 
(3·9 to 8·1)
–2·3% 
(–3·8 to –0·5)
16·7% 
(14·6 to 18·5)
–1·3% 
(–3·0 to 1·1)
Sub-Saharan 
Africa
723 000 
(558 000 to 
927 000)
487 000 
(371 000 to 
621 000)
1 210 000 
(929 000 to 
1 540 000)
362 000 
(333 000 to 
392 000)
349 000 
(327 000 to 
375 000)
712 000 
(669 000 to 
759 000)
–2·8% 
(–3·8 to –1·9)
–5·9% 
(–8·2 to –3·6)
7·8% 
(7·0 to 8·7)
–11·1% 
(–11·5 to –10·6)
Central 
sub-Saharan 
Africa
32 100 
(17 800 to 
52 300)
17 200 
(10 100 to 
27 500)
49 300 
(27 900 to 
80 100)
27 700 
(24 200 to 
31 800)
16 600 
(14 600 to 
18 700)
44 300 
(39 000 to 
50 400)
–2·9% 
(–4·6 to –1·3)
–7·1% 
(–12·3 to –2·9)
3·4% 
(2·1 to 4·7)
–9·1% 
(–10·2 to –7·8)
Angola 12 600 
(4910 to 
22 200)
6380 
(2680 to 
11 300)
19 000 
(7540 to 
32 800)
9750 
(7300 to 
12 700)
4840 
(3670 to 
6290)
14 600 
(11 100 to 
18 900)
12·4% 
(6·2 to 20·4)
–6·3% 
(–16·5 to 0·6)
21·7% 
(17·2 to 24·7)
0·3% 
(–1·0 to 1·7)
Central 
African 
Republic
3470 
(705 to 7620)
1520 
(325 to 3400)
4990 
(1070 to 11 000)
3050 
(2480 to 
3810)
2270 
(1880 to 
2770)
5320 
(4490 to 
6520)
–7·8% 
(–11·0 to –5·5)
–3·1% 
(–18·5 to 4·5)
5·4% 
(3·4 to 7·9)
–10·4% 
(–11·9 to –8·9)
Congo 
(Brazzaville)
4390 
(3070 to 
5940)
2570 
(1820 to 
3450)
6970 
(4980 to 9250)
3310 
(2570 to 
4140)
2260 
(1850 to 
2780)
5570 
(4460 to 
6850)
–4·5% 
(–6·6 to –1·7)
–2·2% 
(–4·3 to –0·4)
0·9% 
(–1·1 to 2·9)
–4·4% 
(–5·7 to –3·4)
Democratic 
Republic of 
the Congo
9590 
(1920 to 
21 200)
5630 
(1590 to 
12 000)
15 200 
(3500 to 
33 400)
10 100 
(7970 to 
12 900)
6300 
(5080 to 
7870)
16 400 
(13 200 to 
20 600)
–5·3% 
(–7·5 to –2·8)
–10·3% 
(–26·0 to –2·9)
2·0% 
(0·6 to 3·6)
–14·0% 
(–15·7 to –11·6)
Equatorial 
Guinea
1510 
(381 to 3510)
853 
(248 to 2010)
2360 
(618 to 5390)
1090 
(808 to 1500)
665 
(481 to 921)
1750 
(1320 to 2380)
8·2% 
(2·5 to 15·5)
–8·3% 
(–22·7 to –0·3)
17·5% 
(11·9 to 21·1)
–0·8% 
(–3·5 to 1·9)
Gabon 497 
(277 to 872)
228 
(128 to 411)
725 
(404 to 1300)
410 
(282 to 641)
234 
(162 to 355)
644 
(465 to 963)
0·3% 
(–4·0 to 3·7)
–12·8% 
(–16·9 to –7·1)
11·4% 
(9·4 to 13·5)
–17·2% 
(–20·4 to –14·0)
Eastern 
sub-Saharan 
Africa
259 000 
(187 000 to 
361 000)
175 000 
(128 000 to 
243 000)
434 000 
(314 000 to 
603 000)
121 000 
(111 000 to 
134 000)
122 000 
(113 000 to 
132 000)
242 000 
(226 000 to 
263 000)
–5·8% 
(–6·9 to –4·9)
–6·2% 
(–9·3 to –2·5)
5·1% 
(4·1 to 6·3)
–13·9% 
(–14·4 to –13·2)
Burundi 1880 
(410 to 4450)
1160 
(271 to 2610)
3040 
(683 to 7270)
1160 
(859 to 1600)
1460 
(1210 to 1800)
2620 
(2150 to 3300)
–17·8% 
(–24·1 to –10·7)
2·8% 
(–11·6 to 11·2)
10·5% 
(5·8 to 14·1)
–19·9% 
(–22·1 to –16·8)
Comoros 3·3 
(0·1 to 17·7)
10·2 
(0·2 to 58·5)
13·4 
(0·3 to 72·3)
0·3 
(0·0 to 3·1)
1·3 
(0·0 to 10·0)
1·6 
(0·0 to 11·9)
10·4% 
(–4·6 to 35·2)
12·8% 
(0·7 to 23·5)
15·2% 
(2·6 to 41·0)
2·7% 
(–17·5 to 12·5)
Djibouti 474 
(132 to 1030)
345 
(99·6 to 744)
820 
(237 to 1720)
415 
(298 to 588)
308 
(222 to 432)
724 
(535 to 987)
14·9% 
(3·8 to 26·9)
–1·5% 
(–12·7 to 5·0)
44·0% 
(32·6 to 59·1)
–6·5% 
(–8·7 to –4·3)
Eritrea 1070 
(267 to 2190)
695 
(202 to 1380)
1770 
(479 to 3570)
944 
(724 to 1220)
577 
(448 to 748)
1520 
(1190 to 1950)
–8·5% 
(–14·8 to –2·3)
1·6% 
(–10·6 to 9·4)
15·2% 
(11·4 to 18·0)
–11·7% 
(–13·5 to –9·8)
Ethiopia 9080 
(4950 to 
14 600)
5400 
(3190 to 
8540)
14 500 
(8280 to 
23 000)
9180 
(7760 to 
10 800)
8000 
(6850 to 
9360)
17 200 
(14 600 to 
20 100)
–18·9% 
(–21·5 to –16·3)
–1·3% 
(–7·6 to 4·1)
7·4% 
(4·6 to 9·6)
–19·7% 
(–20·9 to –18·4)
Kenya 55 900 
(38 000 to 
81 100)
36 900 
(24 300 to 
57 800)
92 800 
(64 000 to 
136 000)
24 700 
(22 400 to 
27 800)
23 800 
(21 800 to 
26 500)
48 500 
(44 600 to 
54 000)
–6·1% 
(–7·5 to –4·8)
–3·5% 
(–6·3 to –0·5)
10·1% 
(9·0 to 11·1)
–11·0% 
(–11·7 to –10·1)
Madagascar 5230 
(585 to 
24 800)
3570 
(438 to 
17 500)
8800 
(1020 to 
42 100)
1450 
(1090 to 
2180)
1080 
(822 to 1680)
2530 
(1920 to 
3820)
18·4% 
(8·0 to 31·5)
9·8% 
(–10·5 to 24·4)
46·0% 
(36·8 to 64·4)
–3·6% 
(–6·5 to –0·5)
Malawi 16 600 
(7920 to 
26 500)
12 000 
(6410 to 
18 600)
28 600 
(14 300 to 
45 200)
10 700 
(8750 to 
13 300)
11 200 
(9620 to 
13 200)
21 900 
(18 900 to 
25 900)
–7·0% 
(–8·5 to –5·5)
–10·8% 
(–18·9 to –5·3)
8·5% 
(6·0 to 11·4)
–17·2% 
(–18·5 to –14·9)
Mozambique 79 100 
(51 900 to 
117 000)
54 000 
(35 400 to 
76 500)
133 000 
(88 800 to 
192 000)
31 700 
(24 300 to 
42 000)
30 400 
(25 400 to 
38 200)
62 100 
(50 600 to 
78 100)
5·4% 
(3·5 to 7·5)
–5·2% 
(–9·5 to –1·7)
18·4% 
(16·0 to 20·6)
–8·0% 
(–9·2 to –6·7)
Rwanda 3930 
(2540 to 
5920)
2390 
(1490 to 
3730)
6320 
(4030 to 9450)
1660 
(1320 to 
2120)
1300 
(1070 to 1690)
2960 
(2460 to 
3710)
–6·1% 
(–9·3 to –2·1)
–7·2% 
(–11·7 to –2·5)
10·2% 
(6·4 to 12·9)
–17·0% 
(–18·1 to –15·3)
Somalia 1320 
(55·4 to 5050)
1060 
(50·4 to 4390)
2380 
(106 to 9370)
1280 
(465 to 4060)
1110 
(402 to 3280)
2390 
(867 to 7270)
–1·4% 
(–10·6 to 7·8)
–5·8% 
(–23·7 to 1·7)
15·6% 
(8·7 to 21·7)
–7·0% 
(–9·8 to –4·6)
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of change in 
new infections
Annualised rate of change in 
HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–17
(Continued from previous page)
South Sudan 2590 
(105 to 9770)
1610 
(60·5 to 5990)
4200 
(162 to 15 700)
2070 
(766 to 6590)
1640 
(536 to 5250)
3710 
(1320 to 
11 600)
0·2% 
(–5·4 to 9·5)
–5·7% 
(–15·6 to –2·9)
13·0% 
(8·9 to 18·2)
–6·6% 
(–10·2 to –3·5)
Tanzania 31 000 
(1470 to 
97 700)
19 400 
(1350 to 
61 800)
50 500 
(2820 to 
159 000)
12 600 
(9670 to 
16 800)
15 700 
(12 200 to 
20 000)
28 300 
(22 700 to 
35 200)
–8·3% 
(–10·8 to –6·0)
–6·6% 
(–41·9 to 7·7)
4·8% 
(3·1 to 6·6)
–17·7% 
(–19·5 to –15·3)
Uganda 24 100 
(3410 to 
84 500)
16 200 
(3020 to 
52 600)
40 300 
(6330 to 
133 000)
12 300 
(10 000 to 
14 900)
13 600 
(11 600 to 
16 500)
25 900 
(22 300 to 
30 500)
–3·8% 
(–7·7 to 0·2)
–11·4% 
(–35·9 to 2·5)
–3·4% 
(–5·0 to –1·2)
–15·7% 
(–16·9 to –13·8)
Zambia 26 600 
(17 800 to 
38 700)
20 200 
(13 400 to 
29 200)
46 800 
(31 600 to 
67 500)
10 300 
(8110 to 
13 000)
11 500 
(9670 to 
14 200)
21 800 
(18 500 to 
26 000)
–5·4% 
(–6·7 to –4·2)
–8·3% 
(–12·2 to –4·2)
5·8% 
(3·4 to 8·5)
–15·5% 
(–16·7 to –13·7)
Southern 
sub-Saharan 
Africa
213 000 
(157 000 to 
281 000)
153 000 
(110 000 to 
201 000)
366 000 
(269 000 to 
470 000)
81 100 
(70 600 to 
93 700)
87 300 
(77 700 to 
98 900)
168 000 
(152 000 to 
189 000)
2·4% 
(0·6 to 3·9)
–5·6% 
(–8·5 to –3·0)
15·0% 
(12·3 to 17·5)
–12·1% 
(–13·1 to –11·1)
Botswana 5230 
(3610 to 7200)
3860 
(2580 to 
5530)
9100 
(6370 to 12 400)
1650 
(1230 to 
2460)
2450 
(1620 to 
3760)
4100 
(3180 to 
5550)
–3·1% 
(–4·5 to –1·8)
–5·3% 
(–9·1 to –1·7)
9·2% 
(6·7 to 12·2)
–14·7% 
(–17·2 to –12·1)
eSwatini 1360 
(324 to 2570)
1000 
(292 to 1850)
2360 
(620 to 4360)
1240 
(1030 to 
1460)
1270 
(1060 to 
1550)
2510 
(2200 to 
2850)
14·2% 
(8·5 to 19·5)
–21·8% 
(–36·1 to –15·1)
35·5% 
(30·6 to 38·5)
–15·4% 
(–17·3 to –12·5)
Lesotho 7280 
(5080 to 
9660)
5390 
(3740 to 7310)
12 700 
(9140 to 
16 700)
3220 
(2620 to 
4060)
3110 
(2510 to 
4050)
6330 
(5330 to 
7830)
2·8% 
(1·1 to 4·5)
–7·1% 
(–10·7 to –4·4)
17·9% 
(15·6 to 20·5)
–10·9% 
(–11·9 to –9·2)
Namibia 5450 
(3180 to 
8970)
3950 
(2320 to 
6350)
9400 
(5550 to 15 100)
2090 
(1390 to 
3130)
1870 
(1400 to 
2540)
3960 
(3020 to 
5290)
2·4% 
(0·8 to 5·1)
–5·8% 
(–10·8 to –1·2)
13·2% 
(8·9 to 16·4)
–12·4% 
(–14·6 to –10·1)
South Africa 160 000 
(120 000 to 
205 000)
116 000 
(85 900 to 
151 000)
276 000 
(211 000 to 
346 000)
64 600 
(54 900 to 
77 300)
70 800 
(61 300 to 
82 200)
135 000 
(119 000 to 
156 000)
12·8% 
(11·3 to 14·2)
–5·7% 
(–7·9 to –3·8)
34·0% 
(32·5 to 35·3)
–10·5% 
(–11·6 to –9·4)
Zimbabwe 33 900 
(1130 to 
76 700)
22 300 
(1100 to 
51 200)
56 300 
(2210 to 
124 000)
8300 
(6710 to 
10 300)
7760 
(6530 to 
9630)
16 100 
(13 900 to 
18 900)
–8·5% 
(–11·0 to –6·3)
–3·0% 
(–40·1 to 7·9)
7·5% 
(5·0 to 10·0)
–20·8% 
(–22·9 to –17·4)
Western 
sub-Saharan 
Africa
218 000 
(152 000 to 
290 000)
142 000 
(99 500 to 
190 000)
360 000 
(258 000 to 
470 000)
133 000 
(111 000 to 
160 000)
124 000 
(106 000 to 
145 000)
257 000 
(223 000 to 
294 000)
–1·6% 
(–3·1 to –0·2)
–4·9% 
(–7·4 to –2·5)
10·2% 
(8·0 to 11·8)
–6·7% 
(–7·3 to –6·1)
Benin 2090 
(1140 to 3250)
1320 
(743 to 2090)
3420 
(1870 to 5220)
1090 
(801 to 1500)
719 
(550 to 951)
1810 
(1380 to 2390)
4·2% 
(0·5 to 13·5)
–5·0% 
(–10·2 to –0·6)
24·8% 
(21·8 to 27·2)
–13·2% 
(–15·0 to –11·3)
Burkina Faso 1890 
(404 to 3830)
1240 
(314 to 2530)
3140 
(725 to 6210)
1060 
(775 to 1460)
1580 
(1240 to 2010)
2640 
(2080 to 
3380)
–15·1% 
(–17·7 to –12·9)
–6·8% 
(–25·2 to 1·7)
–1·3% 
(–3·2 to 1·2)
–16·9% 
(–18·4 to –15·0)
Cameroon 18 800 
(5450 to 
30 900)
10 400 
(3390 to 
17 400)
29 100 
(8970 to 
47 100)
12 300 
(9480 to 
16 200)
10 500 
(8550 to 
13 400)
22 800 
(18 600 to 
28 800)
3·6% 
(1·8 to 5·3)
–6·7% 
(–18·4 to –2·1)
14·0% 
(12·2 to 15·6)
–7·9% 
(–9·5 to –6·4)
Cape Verde 170 
(114 to 239)
155 
(103 to 227)
324 
(229 to 459)
57·2 
(30·8 to 95·5)
67·6 
(47·5 to 98·3)
125 
(83·5 to 187)
–3·1% 
(–5·0 to –1·2)
–0·1% 
(–1·8 to 1·5)
8·2% 
(6·5 to 9·8)
–6·5% 
(–8·9 to –4·3)
Chad 5040 
(1940 to 
8830)
3520 
(1330 to 
5960)
8560 
(3260 to 
14 700)
2500 
(1710 to 
3620)
2430 
(1830 to 
3270)
4930 
(3660 to 
6780)
–5·4% 
(–8·7 to –2·1)
–4·5% 
(–15·0 to 0·7)
9·3% 
(5·4 to 12·5)
–10·6% 
(–12·2 to –9·0)
Côte d’Ivoire 27 300 
(4380 to 
48 500)
18 000 
(3000 to 
31 800)
45 200 
(7400 to 
80 300)
8520 
(5650 to 
11 900)
10 300 
(8000 to 
13 400)
18 800 
(13 700 to 
25 000)
–7·6% 
(–11·0 to 0·6)
–0·4% 
(–17·4 to 7·5)
2·3% 
(–2·1 to 6·1)
–9·3% 
(–11·4 to –7·0)
The Gambia 718 
(225 to 1300)
492 
(153 to 899)
1210 
(375 to 2150)
424 
(285 to 633)
458 
(342 to 632)
883 
(644 to 1220)
9·2% 
(6·5 to 12·3)
–8·3% 
(–19·6 to –3·3)
21·0% 
(18·4 to 23·3)
–4·3% 
(–6·2 to –2·5)
Ghana 15 900 
(8840 to 
26 000)
7210 
(3910 to 
12 300)
23 100 
(12 700 to 
37 900)
8190 
(6480 to 
10 600)
5690 
(4540 to 
7190)
13 900 
(11 200 to 
17 500)
–4·4% 
(–6·0 to –2·8)
–3·0% 
(–8·5 to 1·6)
6·7% 
(3·5 to 9·6)
–8·2% 
(–9·3 to –7·2)
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forecasts to determine whether countries were on track to 
meet the 2020 and 2030 UNAIDS targets.
Uncertainty analysis
We propagated uncertainty by generating 1000 draws of 
key inputs, including draw-level linkage of HIV-free 
mortality with the GBD all-cause mortality process. We 
ran EPP and Spectrum 1000 times per location to 
generate results for each draw. We present results with 
95% uncertainty intervals (UIs).
Role of the funding source
The funder of the study had no role in study design, 
data collection, data analysis, data interpretation, or the 
writing of the report. All authors had full access to 
the data in the study and had final responsibility for the 
decision to submit for publication
Results
Global deaths from HIV peaked in 2006 and have since 
decreased from 1·95 million (95% UI 1·87–2·04) deaths 
in 2006 to 0·95 million (0·91–1·01) in 2017 (figure 1). 
Global ART coverage increased from 2·98 million 
(2·44–3·58) in 2006 to 21·8 million (20·7–22·9) in 2017. 
The number of new HIV infection cases peaked in 1999 
(3·16 million [2·79–3·67]) and has gradually decreased 
thereafter. Between 2007 and 2017, the global age-
standardised annualised rate of change in HIV incidence 
decreased by 3·0% (1·5–4·5), with the number of new 
cases decreasing from 2·35 million (2·02–2·76) in 2007 
to 1·94 million (1·63–2·29) in 2017 (table, figure 1). The 
confluence of these trends produces a steady increase in 
the total number of people living with HIV. Prevalence 
has increased from 8·74 million (7·90–9·68) people 
living with HIV in 1990 to 36·8 million (34·8–39·2) in 
2017, of whom 40·5% (37·8–43·7) were not on ART.
In both 2007 and 2017, younger adults (aged 25–49 years) 
comprised a high percentage of all HIV deaths compared 
with all other age groups (figure 2). Our estimates 
highlight differences in HIV burden between males and 
females. Females aged 30–34 years had the highest 
percentage of HIV deaths of all female age groups, 16·4% 
(95% UI 15·7–16·9) in 2007 and 14·9% (13·8–15·7) in 
2017, whereas males aged 35–39 years had the highest 
percentage of HIV deaths of all male age groups, 
15·9% (14·9–16·8) in 2007 and 14·8% (13·8–15·8) in 2017. 
New HIV infections, 2017 HIV deaths, 2017 Annualised rate of change in 
new infections
Annualised rate of change in 
HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–17
(Continued from previous page)
Guinea 3720 
(2010 to 6010)
1980 
(1100 to 
3180)
5700 
(3150 to 9090)
1750 
(1280 to 
2400)
1240 
(950 to 1620)
2990 
(2280 to 
3920)
4·3% 
(1·5 to 7·5)
–8·2% 
(–13·8 to –4·5)
13·2% 
(10·2 to 15·6)
–8·7% 
(–10·5 to –6·9)
Guinea-
Bissau
1460 
(516 to 2760)
875 
(314 to 1670)
2330 
(847 to 4320)
771 
(536 to 1140)
669 
(478 to 949)
1440 
(1040 to 
2040)
8·3% 
(6·5 to 10·4)
–7·8% 
(–17·0 to –2·7)
14·4% 
(12·7 to 16·1)
–5·0% 
(–7·0 to –2·8)
Liberia 1410 
(592 to 2500)
950 
(393 to 1740)
2360 
(1030 to 4090)
892 
(682 to 1180)
948 
(780 to 1170)
1840 
(1500 to 2310)
–7·8% 
(–17·1 to 4·7)
2·2% 
(–5·5 to 10·7)
14·5% 
(7·7 to 19·8)
–8·9% 
(–11·3 to –6·3)
Mali 4610 
(3100 to 
6430)
3170 
(2130 to 
4390)
7780 
(5300 to 
10 500)
3100 
(2260 to 
4070)
2710 
(2180 to 
3390)
5810 
(4580 to 
7350)
–0·3% 
(–6·7 to 6·0)
–4·9% 
(–7·2 to –2·9)
13·1% 
(8·5 to 16·3)
–5·3% 
(–6·9 to –4·1)
Mauritania 17·4 
(0·4 to 101)
51·9 
(1·1 to 311)
69·3 
(1·8 to 377)
3·3 
(0·1 to 13·5)
16·3 
(0·2 to 161)
19·6 
(0·4 to 179)
–5·1% 
(–20·1 to 13·7)
–1·8% 
(–11·4 to 6·9)
–5·8% 
(–18·2 to 8·6)
–5·0% 
(–20·5 to 3·9)
Niger 1140 
(606 to 1810)
808 
(434 to 1340)
1950 
(1080 to 3020)
910 
(683 to 1170)
1040 
(867 to 1300)
1950 
(1650 to 
2360)
–4·8% 
(–8·7 to –1·7)
–4·5% 
(–9·3 to 0·2)
16·1% 
(14·1 to 17·6)
–12·6% 
(–14·2 to –10·6)
Nigeria 128 000 
(88 000 to 
172 000)
88 800 
(61 800 to 
121 000)
217 000 
(157 000 to 
284 000)
87 500 
(67 200 to 
111 000)
81 600 
(64 000 to 
102 000)
169 000 
(137 000 to 
206 000)
0·3% 
(–1·5 to 1·9)
–5·1% 
(–7·4 to –2·7)
15·3% 
(13·1 to 17·9)
–5·2% 
(–6·0 to –4·5)
São Tomé 
and Principe
0·4 
(0·1 to 0·9)
1·2 
(0·2 to 2·7)
1·5 
(0·4 to 3·5)
0·0 
(0·0 to 0·1)
0·2 
(0·1 to 0·3)
0·2 
(0·1 to 0·4)
–5·2% 
(–16·5 to 4·7)
–0·5% 
(–10·6 to 7·7)
0·5% 
(–5·2 to 8·0)
–10·8% 
(–15·5 to –5·5)
Senegal 1830 
(1090 to 2770)
1040 
(623 to 1560)
2870 
(1740 to 4320)
983 
(721 to 1330)
821 
(655 to 1060)
1800 
(1410 to 2350)
0·4% 
(–1·8 to 2·4)
–5·3% 
(–8·8 to –2·3)
14·2% 
(12·1 to 16·0)
–9·1% 
(–10·9 to –7·6)
Sierra Leone 1800 
(222 to 4070)
1160 
(134 to 2710)
2960 
(371 to 6670)
1140 
(807 to 1580)
1050 
(818 to 1400)
2190 
(1720 to 2850)
18·5% 
(8·6 to 35·2)
–11·4% 
(–34·2 to –4·0)
28·6% 
(22·0 to 32·1)
–5·3% 
(–8·2 to –2·4)
Togo 2430 
(423 to 5400)
1260 
(272 to 2630)
3680 
(695 to 7790)
1920 
(1460 to 
2590)
1950 
(1530 to 
2450)
3870 
(3110 to 
4960)
–1·0% 
(–3·6 to 1·4)
–10·2% 
(–27·8 to –2·4)
16·4% 
(13·9 to 18·8)
–13·0% 
(–14·7 to –11·0)
Data are n (95% UI) or % (95% UI). SDI=socio-demographic index. UI=uncertainty interval. GBD=Global Burden of Diseases, Injuries, and Risk Factors study.
Table: Number of HIV incident cases and deaths in 2017 by sex and annualised rate of change of HIV incident cases and deaths for 1990–2007 and 2007–17, for 21 GBD regions and 
195 countries and territories
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New infections among women were mostly among 
younger adults, with 20·8% (19·2–22·4) of new infections 
occurring among females aged 20–24 years in 2017, 
relatively unchanged from the incidence in 2007 
(20·9%, 19·8–22·1). In 2017, males aged 25–29 years had 
the highest incidence of all male age groups, accounting 
for 18·6% (16·1–23·1) of new infections that year, which 
is a substantial change from 2007, when the highest 
incidence in males occurred among those younger than 
1 year. Although HIV infections in children have 
decreased substantially with the scale-up interventions 
for prevention of mother-to-child transmission, in 2017, 
139 555 (121 893–159 064) new infections were in children 
younger than 1 year, and 122 254 (112 228–132 591) HIV 
deaths were in children younger than 15 years. Most HIV 
deaths in people younger than 15 years are in children 
younger than 5 years, but this proportion has decreased 
from 82·1% (82·0–82·1) in 2007 to 63·4% (60·8–65·8) in 
2017, showing the increase in lifespan for children who 
are HIV positive.
Along with substantial variation in ART coverage 
(figure 3), sub-Saharan Africa had the highest prevalence 
of HIV in 2017 (figure 4). Males in three countries 
(Gabon, eSwatini, and Zimbabwe) and females in 
five countries (Gabon, Rwanda, Botswana, eSwatini, and 
Zimbabwe) with HIV prevalences of greater than one per 
1000 population reached ART coverage of 81% or higher 
in 2017, reflecting early attainment of the second 90 of 
the UNAIDS 90-90-90 targets (figure 3). Countries across 
southern sub-Saharan Africa achieved higher proportions 
of treatment coverage than those in other sub-Saharan 
African regions, ranging from 66% in Lesotho to 86% in 
eSwatini. The estimated proportion of people living with 
HIV who were on treatment was higher among women 
than men in all but eight countries in sub-Saharan Africa 
(Angola, Benin, Cape Verde, Democratic Republic of the 
Congo, Djibouti, Eritrea, Madagascar, and São Tomé and 
Príncipe). Additional results detailing proportions of 
males and females on and off ART by GBD super-region 
are in appendix 2 (pp 25–31). Overall ART coverage has 
increased substantially over the past decade in some 
countries (figure 5). Between 2007 and 2017, 42 countries 
had annualised rates of change in ART coverage greater 
than 25%.
In 2017, South Africa had a higher number of new 
infections than all other countries, with 0·28 million 
(95% UI 0·21 to 0·35) new cases (table). The incidence 
for both sexes was highest in Lesotho in 2017, where the 
age-standardised rate of new cases was 6·2 (4·5 to 8·2) 
per 1000 population (figure 4). From 2007 to 2017, the 
annualised rate of change in incidence in Lesotho was 
–7·1% (95% UI –10·7 to –4·4), which is a drastic change 
from the positive annualised rate of change in incidence 
from 1990 to 2007 (2·8%, 1·1 to 4·5; table). Substantial 
progress has been made by most countries in 
sub-Saharan Africa, and Comoros was the only country 
that had an increase in incidence from 2007 to 2017, with 
an annualised rate of change of 12·8% (0·7 to 23·5). By 
contrast, many countries in eastern Europe and central 
Asia saw a sharp increase in the number of new 
infections in the past decade, with the highest annualised 
rate of change seen in Russia at 13·2% (10·3 to 15·5). 
Most countries in western Europe and North America 
also showed stagnant or increasing annualised rates of 
change in incidence (table).
Between 2007 and 2017, 122 of 195 countries had a 
decrease in the rate of change in age-standardised HIV 
mortality. Notably, the countries that achieved the most 
rapidly decreasing annual rates of change were Ethiopia 
(–19·7%, 95% UI –20·9 to –18·4), Burundi (–19·9%, 
–22·1 to –16·8), and Zimbabwe (–20·8%, –22·9 to –17·4; 
table). Lesotho had the highest age-standardised mortality 
in 2017, with mortality for both sexes combined being 3·4 
(95% UI 3·0 to 4·0) per 1000 population (figure 4). 
The annualised rate of change in mortality between 2007 
and 2017 in Lesotho was –10·9% (–11·9 to –9·2), and 
prevalence in Lesotho increased from 153·2 (142·7 to 164·7) 
per 1000 population in 2007 to 177·8 (168·9 to 187·8) per 
1000 population in 2017 (data available from GBD 
datahub).
In our forecasting, we found that progress towards 
meeting the ART coverage target is more optimistic than 
progress towards the incidence or mortality targets. Global 
Figure 2: Percentage of deaths and new cases of HIV occurring in each age group, by sex, 2007 and 2017
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ART coverage was forecast to be 64·8% (95% UI 61·1–67·0) 
in 2020 and 71·9% (68·2–75·0) in 2030 (appendix 2 
pp 3–12). A substantial number of countries are predicted 
to meet ART coverage targets (figure 6), with 54 countries 
expected to meet the 2020 target of 81% ART coverage 
(90% started, 90% retained) and 12 expected to meet the 
2030 target of 90% ART coverage (95% started, 
95% retained). Of the 54 countries forecast to meet the 
2020 ART coverage target, 25 are in the high-income 
super-region; 11 are in central Europe, eastern Europe, and 
central Asia; ten are in sub-Saharan Africa; six are in Latin 
America and the Caribbean; and two are in other regions 
(Mauritius and Kuwait; figure 6; appendix 2 pp 3–12). 
Looking ahead, 38 countries had a forecast coverage of at 
least 85% but less than the 90% target in 2030.
Compared with ART coverage, fewer countries are 
expected to achieve the UNAIDS 2020 or 2030 targets 
associated with mortality (figure 7; appendix 2 pp 13–18). 
Six countries (Burundi, Ethiopia, Gabon, eSwatini, 
Zambia, and Zimbabwe) were forecasted to achieve the 
2020 target for mortality percentage reduction and two 
(Ethiopia and eSwatini) were forecasted to achieve the 
2030 target. Although still short of the target, an 
additional eight countries (Botswana, Democratic 
Republic of the Congo, India, Cambodia, Myanmar, 
Togo, Tanzania, and South Africa) were forecasted to 
have a reduction in mortality of at least 65% between 
2010 and 2020, and six (Burundi, Botswana, Gabon, 
Cambodia, South Africa, Zambia) were forecasted to 
have a reduction of at least 80% between 2010 and 2030. 
Forecasted trends in incidence show the least progress, 
with no countries meeting the UNAIDS 2030 target 
(figure 7; appendix 2 pp 19–24).
Discussion
Globally, great progress has been made in reducing HIV-
related incidence and mortality since their peaks earlier 
in the epidemic, consistent with the positive trend in 
ART coverage. Despite the scale-up of ART over time, in 
2017, 40·5% (95% UI 37·8–43·7) of the 36·82 million 
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Figure 3: Proportion of people living with HIV who are on and off ART in sub-Saharan Africa, 2017, by country and sex
Countries are subdivided by total HIV prevalences of 27 to 213 per 1000 population (A), 9 to <27 per 1000 population (B), and 0 to <9 per 1000 population (C). 
Proportions given in bar charts are for those on ART. ART=antiretroviral therapy.
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(34·79–39·20) people estimated to be living with HIV 
globally were still not on treatment. In the same year, 
1·94 million (1·63–2·29) people were newly infected 
with HIV and 0·95 million (0·91–1·01) people died from 
HIV-related causes. Trends in new infections and 
mortality are our primary indicators of progress, and 
over the past decade HIV incidence has been decreasing 
more slowly than mortality. Thus, decreases will need to 
be accelerated to achieve global targets. Although 
54 countries are on track to meet the 2020 target of 
81% ART coverage (90% started, 90% retained), only 
12 countries are expected to meet the 2030 target of 
90% ART coverage (95% started, 95% retained). Our 
forecasts show that fewer than ten countries will meet 
the mortality or incidence targets in 2020 and 2030.
Annualised rates of change in age-standardised HIV 
incidence and mortality between 2007 and 2017 varied 
considerably across countries. The substantial decreases 
in many sub-Saharan African countries underscore the 
enormous effort by governments and multilateral 
organisations to improve HIV prevention and provide 
effective treatment in these countries. For example, in 
Zimbabwe, high levels of personal exposure to AIDS 
deaths and prevention campaigns coupled with a 
relatively well educated population appear to have 
shifted social norms and catalysed partner reduction, 
which are thought to have contributed to steep decreases 
in HIV prevalence.14 eSwatini saw success after 
implementation of a multisectoral response with invest-
ments that prioritised ART scale-up, voluntary medical 
male circumcision, and prevention interventions aimed 
at adolescent women, mother-to-child transmission of 
HIV, and tuberculosis–HIV co-infection.15 Scale-up of a 
combination strategy of ART and medical male 
circumcision, funded by the President’s Emergency 
Plan for AIDS Relief (PEPFAR), was found to have 
population-level impact in Uganda in reducing 
incidence.16 Decreases in HIV burden in Botswana have 
been attributed to nearly complete coverage of 
interventions for prevention of mother-to-child 
transmission and expansion of ART, which might also 
have reduced stigma.17
Conversely, between 2007 and 2017 many countries in 
eastern Europe and central Asia saw increasing rates of 
new HIV infections and persistently high mortality; 
Russia reached the highest annual increase in incidence 
at 13·2% (95% UI 10·3–15·5). The growing epidemic 
seen in much of eastern Europe and central Asia stems 
from multiple factors, including limited access to ART, 
inadequate access to harm-reduction services (eg, needle 
and syringe programmes, and opioid substitution 
therapy), and high levels of stigma.18 Opioid substitution 
Figure 4: Age-standardised HIV incidence (A), prevalence (B), and mortality (C) for both sexes, 2017
ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. Isl=islands. FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste.
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treatment has been shown to lead to substantial 
reductions in risk of HIV infection among people who 
inject drugs; however, opioid substitution therapy 
remains unavailable in Russia.19 The particularly steep 
increases in new infections in Russia could also be linked 
to poor access to care for high-risk populations and 
elimination of Global Fund support.20
Our results showed stagnant or increasing annualised 
rates of change in incidence in many countries in 
western Europe and North America. In these countries, 
the HIV epidemic is largely driven by men who have sex 
with men (MSM).21 Challenges in the scale-up of HIV 
prevention programmes for MSM have been reported, 
including limited access to HIV testing and care and 
financial barriers.22 For example, the US Centers for 
Disease Control and Prevention estimated that MSM 
accounted for 66% of all HIV diagnoses in 2017 in the 
USA, and studies have shown high proportions of MSM 
are unaware of their status.23,24 Increasing testing among 
high-risk populations is paramount to HIV prevention, 
because those who are aware of their status can decrease 
the risk of future transmission.24,25 Additionally, increases 
in injection drug use in the USA have been linked with 
HIV outbreaks, and treatment efforts could be improved 
because fewer than 10% of those dependent on opioids 
are receiving substitution therapy.26
We found higher proportions of new infections among 
younger women (aged 20–24 years) than in men of the 
same age group in 2017. Higher risk of HIV infection 
among young women than in young men has been 
Figure 5: All-age annualised rate of change of ART coverage between 2007 and 2017, both sexes
ART=antiretroviral therapy. ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. Isl=islands. FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago. 
TLS=Timor-Leste.
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Figure 6: Forecast of percentage ART coverage in 2020 and 2030, by country
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linked to several factors, including social factors such as 
poverty and low education, cultural factors such as 
transactional sex, laws that deter young women from 
accessing sexual and reproductive health services, and 
exposure to intimate partner violence.27,28 Ambitious 
interventions that address multiple causes of young 
women’s vulnerability to HIV infection in sub-Saharan 
African countries are underway.29
Few countries are on track to meet the global targets for 
incidence. Achieving reductions in incidence is complex 
because it requires increased coverage for both 
prevention and treatment interventions. A large body of 
literature has explored various intervention options.30 
The HIV prevention cascade has been proposed as a 
novel framework to guide and monitor the design of 
interventions to maximise coverage at the population 
level. Krishnaratne and colleagues30 found that direct 
interventions, including overall pre-exposure prophylaxis 
medications and medical male circumcision, were 
efficacious for reducing incidence. Additionally, the 
consensus statement issued in 2016, and endorsed by 
over 760 organisations to date, states that undetectable 
viral load is equivalent to non-transmittable infection 
based on strong scientific evidence that HIV cannot be 
transmitted sexually by those with an undetectable viral 
load.31 This evidence suggests that increasing access to 
early treatment and interventions to improve adherence 
can support further decreases in incidence. Still, few 
countries are forecast to achieve the 2030 ART coverage 
target of 95% covered and 95% retained.
Although treatment access and prevention mechanisms 
exist and can be widely implemented, inadequate ART 
coverage and adherence could perpetuate the AIDS 
epidemic. Achieving exceptionally high ART coverage 
involves reaching groups that are difficult to target for 
testing and treatment. We estimate substantially lower 
ART coverage among men across most of sub-Saharan 
Africa than in other regions, which could stem from 
tendencies among men to delay presentation to testing 
and care.32 Additionally, in many parts of sub-Saharan 
Africa and other high-burden locations, large rural 
catchment areas further compound barriers to HIV 
treatment services. Developments in the area of 
geospatial modelling point to emerging oppor tunities to 
improve access and delivery of health interventions at the 
population level.33
Despite the substantial progress made in reducing 
HIV-related mortality globally, only a small number of 
Figure 7: Forecast percentage decrease in HIV mortality (A) and incidence (B) from 2010 to 2020 and 2030, by country
Each datapoint is a country. The plots are truncated at 100% increase, so in (A) 47 countries have been excluded and in (B) 35 countries have been excluded.
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countries are on track to meet the 2020 and 2030 
mortality targets. To accelerate the decrease in HIV-
related mortality, prevention, early detection, and 
treatment of opportunistic infections such as tuberculosis 
should be a priority. Integration of services for HIV and 
tuberculosis, a leading cause of mortality among people 
living with HIV, is crucial as a strategy to increase linkage 
to HIV care and tackle the double burden of HIV and 
tuberculosis.34
These findings should be viewed in the context of 
global financing for HIV/AIDS. The excitement around 
the MDGs and the goal to achieve universal access to 
treatment for HIV/AIDS by 2010 catalysed substantial 
resources to tackle the epidemic. Our estimates are 
consistent with the positive results of such global 
investment. However, the current and future costs of 
HIV/AIDS interventions and the ability of stakeholders 
to meet global needs will affect the epidemic going 
forward.
Moreover, the costs of the epidemic are likely to change. 
In 2015, US$27·3 billion was spent globally on HIV/
AIDS care and treatment, amounting to more than 
half (55·8%) of the $48·9 billion spent on HIV/AIDS 
annually.1 HIV care and treatment includes services in 
both inpatient and outpatient settings, financed primarily 
through government spending and externally sourced 
develop ment assistance for health. With access to ART, 
extended lifespans could continue to increase the total 
number of people living with HIV and thus further 
increase demand for treatment. Although the 
development of new therapies might reduce the per-
person cost to treat those living with HIV, drug resistance 
that is emerging alongside increased access to ART could 
compound progress by increasing the cost of treatment 
and necessitating additional resistance testing on a wider 
scale.35 Therefore, decision makers need to anticipate the 
costs of providing treatment and look to prioritise 
prevention to reduce future costs. The GBD Health 
Financing Collaborator Network assessed that the 
annualised rate of support per prevalent case had 
increased between 2000 and 2010 but had subsequently 
decreased between 2010 and 2015.1 The gap that exists 
between available resources and what is needed to 
achieve global targets will require renewed mobilisation 
of resources, otherwise the decrease in development 
assistance for HIV/AIDS could hinder progress.
Although UNAIDS and GBD use similar approaches to 
modelling the burden of HIV, key differences exist in 
data and methods. At the global level, UNAIDS and GBD 
estimate similar mortality and prevalence; however, GBD 
estimates slightly higher incidence.36 Incidence in recent 
years is difficult to estimate because of the paucity of data 
and need to infer incidence from prevalence data. 
Therefore, recent estimates are highly sensitive to model 
specification. For group 2 countries, one primary data 
difference is that the GBD uses vital registration data as 
an input for models, using a uniform approach to 
cleaning data, accounting for garbage coding, and 
generating full time-series estimates of HIV mortality 
with uncertainty. While some countries might use vital 
registration data when producing official UNAIDS 
estimates, not all countries with data of sufficient quality 
include it as an input in their model, and heterogeneous 
data processing restricts com parability. Another method-
ological difference is that for allocation of ART to 
different ages, sexes, and disease severity levels, UNAIDS 
uses an average of the expected number of deaths and 
the number of people in each untreated CD4 count group 
to allocate ART, whereas GBD uses a model to determine 
the association between a country’s economic status and 
the allocation of treatment.
Globally, more than one in eight new HIV infections 
occur in South Africa, making global trends highly 
sensitive to differences in estimates for South Africa. 
UNAIDS estimates for South Africa are based on a 
bespoke epidemic model (Thembisa), which differs in 
its complexity and input data from the model used for 
the rest of sub-Saharan Africa.37 The Thembisa-based 
model estimates a lower peak of incidence (13·81 in 1999 
in UNAIDS estimates vs 14·58 per 1000 in 2000 in GBD 
estimates), a steeper decrease in incidence between 2007 
and 2012 (–28% in UNAIDS estimates vs –12% in GBD 
estimates), and a slower decrease in incidence between 
2012 and 2017 than GBD does (–28% in UNAIDS 
estimates vs –34% in GBD estimates).36 Similarly, the 
same model estimates a faster decrease in the number of 
deaths between 2007 and 2012 (–50% in UNAIDS 
estimates vs –23% in GBD estimates), and a slower 
decrease in deaths between 2012 and 2017 (–29% in 
UNAIDS estimates vs –45% in GBD estimates).36
This study has several limitations. First, our incidence 
and prevalence estimates in countries with vital 
registration data are driven by back-estimation from 
mortality data using assumptions of disease progression 
and survival. This estimation process relies on knowledge 
of the distribution of deaths occurring in each year for 
each incidence cohort. The back-calculation is inherently 
uncertain in more recent years when a smaller proportion 
of each incidence cohort has died. Second, for countries 
without prevalence data for which we do not run EPP, we 
must run a first stage of Spectrum using input incidence 
estimates. Our final prevalence results have shown 
considerable sensitivity to this initial incidence. We have 
attempted to mitigate this sensitivity by testing several 
options for input incidence and selecting the one that 
produces the closest fit to mortality data for each location, 
yet we expect that sensitivity to input incidence might 
still result in overestimated HIV burden in some 
locations, such as Portugal. Third, in group 1 countries, 
we have little cause-specific mortality data and rely on 
prevalence data and HIV mortality data derived from 
cohort studies to model HIV deaths. This limitation is 
reflected by wider UIs for results in these locations. For 
on-ART mortality, we pooled data from across countries 
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in sub-Saharan Africa, and although this process results 
in reliable regional estimates, it means that our model 
does not incorporate variation in treatment quality or 
health system access by country. Fourth, importantly, our 
estimates are subject to the data available at the time of 
analysis. New data sources will be incorporated in future 
iterations of analyses as they become available. Finally, 
although our forecasted incidence accounts for direct 
effects of ART in reducing a first generation of 
transmission, they do not incorporate compounding 
secondary transmission dynamic effects.
Despite these limitations, we made several improve-
ments in our methods compared with previous GBD 
analyses. In GBD 2017, we modelled ART coverage 
distribution in Spectrum as a function of national wealth 
and disease progression. Whereas previous iterations of 
GBD used a version of Spectrum that disproportionately 
allocated ART to those with lower CD4 counts, the new 
model reflects earlier access to treatment regardless of 
disease progression for people living with HIV in higher-
income countries. We also improved our estimation of 
paediatric HIV burden by modelling natural disease 
progression and informing child ART initiation and 
mortality using cohort data. Additionally, previous 
iterations assumed the same sex distribution of HIV 
burden across countries with generalised epidemics, but 
we now use a model fit to the sex ratio of prevalence from 
representative surveys to better reflect geographical 
variation.
Despite the considerable progress made in reducing 
HIV-related mortality and increasing the coverage of 
ART, HIV continues to be an enormous health burden 
globally. Up-to-date information on the trends of the HIV 
epidemic from the GBD 2017 study provides an 
opportunity to track the success of HIV control efforts 
and understand where interventions are having an 
impact. Our results show that decreases in mortality have 
out-paced decreases in incidence, therefore much needs 
to be done to prevent new cases of HIV. Additionally, at 
their current rates, many countries are not on track to 
reach the 2020 and 2030 UNAIDS and SDG targets. To 
truly end the HIV epidemic, the pace of progress needs to 
increase. Strides in this direction can be made by 
continuing to expand universal access to ART and 
increasing investments in proven HIV prevention 
initiatives that can scale to have population-level effects.
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